

## Prof. Faruk TAŞ

### Personal Information

**Other Email:** faruktas2002@yahoo.com

**Web:** <http://aves.istanbul.edu.tr/1534/>

### International Researcher IDs

ScholarID: H8Vp8swAAAAJ

ORCID: 0000-0001-6514-7116

Publons / Web Of Science ResearcherID: AAF-8751-2019

ScopusID: 7004030463

Yoksis Researcher ID: 200359

### Education Information

Post Doctorate of Medicine, Istanbul University, Onkoloji Enstitüsü, Tıbbi Onkoloji, Turkey 1995 - 1998

Expertise In Medicine, Istanbul University, Istanbul Medical Faculty, İç Hastalıkları, Turkey 1986 - 1990

Undergraduate, Istanbul University, Cerrahpaşa Tıp Fakültesi, Turkey 1980 - 1986

### Dissertations

Expertise In Medicine, Meme Kanserinde Anjiogenez ve p53 Proteinini: Prognostik Değerleri ve Etkileşimleri, Istanbul University, Onkoloji Enstitüsü, Tıbbi Onkoloji, 1988

### Research Areas

Medicine, Internal Medicine Sciences, Internal Diseases, Oncology, Health Sciences

### Academic Titles / Tasks

Professor, Istanbul University, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı, 2006 - Continues

Associate Professor, Istanbul University, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı, 2000 - 2006

Expert PhD, Istanbul University, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı, 1995 - 2000

Research Assistant PhD, Istanbul University, Istanbul Medical Faculty, Division of Medical Sciences , 1986 - 1990

Student, İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, 1980 - 1986

### Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Prognostic significance of body mass index and serum albumin as the indicators of nutritional status in small cell lung cancer.**  
Tas F., Ozturk A., Erturk K.  
Postgraduate medicine, 2024 (SCI-Expanded)
- II. **Comorbidity in Small Cell Lung Cancer: Prognostic Impacts of Hypertension/Coronary Artery Disease, Diabetes Mellitus, and Chronic Obstructive Pulmonary Disease.**

Tas F., Ozturk A., Erturk K.

Cancer investigation, pp.1-13, 2024 (SCI-Expanded)

- III. **Timing of chemotherapy after diagnosis of small cell lung cancer.**  
Tas F., Ozturk A., Erturk K.  
Journal of chemotherapy (Florence, Italy), pp.1-6, 2024 (SCI-Expanded)
- IV. **Effect of Histological Subtype on Metastasis Distribution in Resected Cutaneous Melanoma**  
Tas F.  
INDIAN JOURNAL OF DERMATOLOGY, vol.69, no.1, pp.107, 2024 (SCI-Expanded)
- V. **Median Age of Cutaneous Melanoma Presentation in Turkey from a Single Tertiary Center Is Younger Than Other Western Countries**  
TAŞ F., Erturk K.  
INDIAN JOURNAL OF SURGERY, vol.85, no.4, pp.1010-1011, 2023 (SCI-Expanded)
- VI. **Neither the presence nor the severity of hyponatremia affected the outcome of the patients with small cell lung cancer.**  
Tas F., Ozturk A., Erturk K.  
Irish journal of medical science, vol.192, no.4, pp.1613-1619, 2023 (SCI-Expanded)
- VII. **Breast cancer patients are diagnosed at younger ages in Turkey: a comparative study.**  
Tas F., Erturk K.  
Irish journal of medical science, vol.192, no.3, pp.1073-1075, 2023 (SCI-Expanded)
- VIII. **Completion Lymph Node Dissection Is Unnecessary After Positive Sentinel Lymph Node in Melanoma — a Case Series Analysis**  
TAŞ F., Erturk K., Ferhatoglu F.  
Indian Journal of Surgery, vol.85, no.3, pp.570-574, 2023 (SCI-Expanded)
- IX. **Turkey's contribution to cancer publication: Expected quantity, unsatisfactory quality.**  
Tas F., Erturk K.  
Journal of cancer research and therapeutics, vol.19, no.Supplement, 2023 (SCI-Expanded)
- X. **Using Google as a Source of Information About Breast Cancer**  
Tas F., Erturk K.  
INDIAN JOURNAL OF SURGERY, vol.85, no.2, pp.473-475, 2023 (SCI-Expanded)
- XI. **Cutaneous melanoma survival rates of the elderly are not worse than those of the young, yet they have some specific differences**  
Ferhatoglu F., Erturk K., Taş F.  
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.19, no.(Suppl 1), pp.349-354, 2023 (SCI-Expanded)
- XII. **Primary tumor SUV(max) and ratio of SUV(max) to primary tumor size on pretreatment 18F-FDG-PET/CT scan in small cell lung cancer : Which is superior for the prognosis?**  
Tas F., Ozturk A., Erturk K.  
Wiener klinische Wochenschrift, 2023 (SCI-Expanded)
- XIII. **Melanoma publications do not increase as much as the incidence of melanoma in the last two decades.**  
Tas F., Erturk K.  
Journal of cancer research and therapeutics, vol.19, no.Suppl 2, 2023 (SCI-Expanded)
- XIV. **Diagnosing lung cancer at a younger age and with male dominance: Comparison of Turkish patients with United States patients.**  
Tas F.  
Journal of cancer research and therapeutics, vol.19, no.Suppl 2, 2023 (SCI-Expanded)
- XV. **Online public interest in smoking and lung cancer: A comparative study in Google Trends.**  
Tas F., Erturk K.  
Journal of cancer research and therapeutics, vol.19, no.Suppl 2, 2023 (SCI-Expanded)
- XVI. **Seasons Influence Diagnosis of Breast Cancer in Turkey**  
Taş F., Erturk K.  
INDIAN JOURNAL OF SURGERY, vol.84, no.6, pp.1364-1365, 2022 (SCI-Expanded)

- XVII. Major Histotypes in Skin Melanoma: Nodular and Acral Lentiginous Melanomas Are Poor Prognostic Factors for Relapse and Survival.**  
Tas F., Erturk K.  
The American Journal of dermatopathology, vol.44, pp.799-805, 2022 (SCI-Expanded)
- XVIII. Successful Treatment of a 92-Year-Old Classic Kaposi's Sarcoma Man With Ultra-Low Dose Oral Etoposide.**  
Tas F., Sakar B.  
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, vol.28, no.7, pp.1671-1673, 2022 (SCI-Expanded)
- XIX. Unknown Primary Metastatic Melanoma Presented with Extensive Subcutaneous Masses and Lymph Node Enlargements**  
Tas F., Erturk K.  
INDIAN JOURNAL OF SURGERY, vol.84, pp.579-580, 2022 (SCI-Expanded)
- XX. Larger Tumors Are Associated with Poorer Prognostic Factors in Cutaneous Melanoma**  
Tas F., Erturk K.  
INDIAN JOURNAL OF SURGERY, vol.84, no.3, pp.591-594, 2022 (SCI-Expanded)
- XXI. Digit melanomas are associated with poor prognostic factors and unfavorable survivals.**  
Tas F., Erturk K.  
Journal of cosmetic dermatology, vol.21, pp.2120-2129, 2022 (SCI-Expanded)
- XXII. Auricular and periauricular melanomas have similar clinicopathologic factors and survival rates.**  
Tas F., Erturk K., Ferhatoglu F.  
Journal of cosmetic dermatology, vol.21, no.4, pp.1570-1573, 2022 (SCI-Expanded)
- XXIII. Different mitotic rates are associated with different prognostic factors, relapses, and survival rates in melanoma.**  
Tas F., Erturk K.  
International journal of dermatology, vol.61, no.4, pp.472-479, 2022 (SCI-Expanded)
- XXIV. Complementary and alternative medicine (CAM) in Turkish cutaneous melanoma patients: A prospective study from tertiary cancer center.**  
Tas F., Cinar E., Erturk K.  
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, vol.28, no.2, pp.282-286, 2022 (SCI-Expanded)
- XXV. Trunk melanomas: no survival differences between lesion sites.**  
Tas F., Erturk K.  
Postgraduate medicine, vol.134, no.6, pp.609-615, 2022 (SCI-Expanded)
- XXVI. Ulceration <i>vs</i> Mitosis in Cutaneous Melanoma: which is Superior for Predicting Prognosis Across Clinical Stages?**  
Tas F., Erturk K.  
Cancer investigation, vol.40, pp.842-851, 2022 (SCI-Expanded)
- XXVII. Limb melanomas: acral melanomas have worse survival.**  
Tas F., Erturk K.  
The Journal of dermatological treatment, vol.33, no.3, pp.1630-1637, 2022 (SCI-Expanded)
- XXVIII. Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma: retrospective real-life data.**  
Gürbüz M., Doğan İ., Akkuş E., Ermiş H., Utkan G., Taş F., Vatansever S.  
Dermatologic therapy, vol.34, no.6, 2021 (SCI-Expanded)
- XXIX. Coexistence of regression and tumor infiltrating lymphocytes is associated with more favorable survival in melanoma.**  
Tas F., Erturk K.  
Journal of cancer research and clinical oncology, vol.147, pp.2721-2729, 2021 (SCI-Expanded)
- XXX. Serum folate and vitamin B12 levels in cutaneous melanoma**  
Tas F., Erturk K., Soydinc H.

JOURNAL OF COSMETIC DERMATOLOGY, vol.20, no.9, pp.3007-3010, 2021 (SCI-Expanded)

- XXXI. **Trends in the characteristics of skin melanoma in accordance with time intervals: A single Turkish tertiary referral center experience.**

Tas F., Erturk K.

Journal of cancer research and therapeutics, vol.17, no.4, pp.1119-1122, 2021 (SCI-Expanded)

- XXXII. **Mitotic rate in node-positive stage III melanoma: it might be as important a prognostic factor as node number.**

Tas F., Erturk K.

Japanese journal of clinical oncology, vol.51, pp.873-878, 2021 (SCI-Expanded)

- XXXIII. **Multiple combinations of melanocytic and vascular endothelial markers enhance the detection rate of lymphovascular invasion in cutaneous melanoma.**

Bayram A., Sari S., Ozluk Y., Tas F., Buyukbabani N.

Journal of cutaneous pathology, vol.48, no.4, pp.472-478, 2021 (SCI-Expanded)

- XXXIV. **Primary tumour ulceration in cutaneous melanoma: its role on TNM stages.**

Tas F., Erturk K.

Japanese journal of clinical oncology, vol.51, pp.192-198, 2021 (SCI-Expanded)

- XXXV. **Serum 25-Hydroxyvitamin D Level Is Not Associated with Duration and Activity of Disease in Melanoma Patients**

Tas F., Erturk K., Oguz S.

NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, vol.73, no.7, pp.1126-1129, 2021 (SCI-Expanded)

- XXXVI. **Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma.**

Tas F., Erturk K.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, vol.27, no.1, pp.40-45, 2021 (SCI-Expanded)

- XXXVII. **Paradox in melanoma: more patients fewer publications.**

Tas F., Erturk K.

Melanoma research, vol.30, pp.632, 2020 (SCI-Expanded)

- XXXVIII. **Awareness on malignant melanoma and its prevention measures among Turkish cutaneous malignant melanoma patients: A tertiary cancer center experience.**

Tas F., Cinar F., Erturk K.

Dermatologic therapy, vol.33, 2020 (SCI-Expanded)

- XXXIX. **Google searching as an indicator of population's interest in melanoma: A comparative study in Google Trends.**

Tas F., Erturk K.

Dermatologic therapy, vol.33, 2020 (SCI-Expanded)

- XL. **Cutaneous melanoma in vicenarians: Patients in their twenties and older patients show similar clinical behaviors and survival rates**

Tas F., Erturk K.

JOURNAL OF COSMETIC DERMATOLOGY, vol.19, pp.2692-2696, 2020 (SCI-Expanded)

- XLI. **De Novo and Nevus-Associated Melanomas: Different Histopathologic Characteristics but Similar Survival Rates.**

Tas F., Erturk K.

Pathology oncology research : POR, vol.26, pp.2483-2487, 2020 (SCI-Expanded)

- XLII. **SEASONS INFLUENCE DIAGNOSIS AND OUTCOME OF CUTANEOUS MELANOMA.**

Tas F., Erturk K.

Dermatologic therapy, vol.33, 2020 (SCI-Expanded)

- XLIII. **BRAF V600E mutation as a prognostic factor in cutaneous melanoma patients.**

Tas F., Erturk K.

Dermatologic therapy, vol.33, 2020 (SCI-Expanded)

- XLIV. **Spitzoid cutaneous melanoma is associated with favorable clinicopathological factors and outcome.**

Tas F., Erturk K.

Journal of cosmetic dermatology, vol.18, pp.1841-1845, 2019 (SCI-Expanded)

- XLV. **Distichiasis in association with entropion in metastatic HER2-positive breast cancer treated by pertuzumab, trastuzumab, and docetaxel combination chemotherapy**  
Tas F., Ozturker C.  
BREAST JOURNAL, 2019 (SCI-Expanded)
- XLVI. **Number of Excised Lymph Nodes Has No Impact on Relapse and Survival in Patients With Stage III Melanoma**  
Tas F., Erturk K.  
ANNALS OF PLASTIC SURGERY, vol.83, no.4, pp.455-458, 2019 (SCI-Expanded)
- XLVII. **BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha**  
Tas F., Erturk K.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.84, no.3, pp.521-526, 2019 (SCI-Expanded)
- XLVIII. **Serum nectin-2 and nectin-4 are diagnostic in lung cancer: which is superior?**  
Erturk K., Karaman S., Dagoglu N., Serilmez M., Duranyildiz D., Tas F.  
WIENER KLINISCHE WOCHENSCHRIFT, no.17-18, pp.419-426, 2019 (SCI-Expanded)
- XLIX. **Clinical and prognostic significance of BRAF V600E mutation in non-metastatic cutaneous melanoma patients.**  
Tas F., Erturk K.  
Neoplasma, vol.66, no.4, pp.631-636, 2019 (SCI-Expanded)
- L. **The course of stage III melanoma in accordance with the severity of node involvement**  
Tas F., Erturk K.  
CURRENT MEDICAL RESEARCH AND OPINION, vol.35, no.10, pp.1819-1824, 2019 (SCI-Expanded)
- LI. **Lymph node ratio has impact on relapse and outcome in patients with stage III melanoma**  
Tas F., Erturk K.  
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.24, no.6, pp.721-726, 2019 (SCI-Expanded)
- LII. **Early and late relapses of cutaneous melanoma patients**  
Tas F., Erturk K.  
POSTGRADUATE MEDICINE, vol.131, no.3, pp.207-211, 2019 (SCI-Expanded)
- LIIL. **Cheek Cutaneous Melanomas A Review of 98 Cases**  
Tas F., Erturk K.  
ANNALS OF PLASTIC SURGERY, vol.82, no.4, pp.407-410, 2019 (SCI-Expanded)
- LIV. **Relapse patterns in patients with local and regional cutaneous melanoma.**  
Tas F., Erturk K.  
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol.21, no.4, pp.412-419, 2019 (SCI-Expanded)
- LV. **Prognostic and Predictive Role of Angiogenic Markers in Non- Small Cell Lung Cancer**  
Keskin S., Kutluk A., Tas F.  
Asian Pacific journal of cancer prevention : APJCP, vol.20, pp.733-736, 2019 (SCI-Expanded)
- LVI. **Palpebral cutaneous melanomas: a review of 17 cases from a tertiary center**  
Tas F., Erturk K.  
INTERNATIONAL JOURNAL OF DERMATOLOGY, vol.58, no.1, pp.75-79, 2019 (SCI-Expanded)
- LVII. **Clinical significance of serum caveolin-1 levels in gastric cancer patients.**  
Tas F., Karabulut S., Erturk K., Duranyildiz D.  
Experimental oncology, vol.40, pp.323-327, 2018 (SCI-Expanded)
- LVIII. **Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer**  
Afsar C. U., Karabulut M., Karabulut S., Ozal S. T., Cikot M., Serilmez M., Tas F.  
BIOMOLECULES, vol.8, no.4, 2018 (SCI-Expanded)
- LIX. **Clinical significance of serum leptin level in patients with gastric cancer**  
Tas F., Karabulut S., Erturk K., Duranyildiz D.

EUROPEAN CYTOKINE NETWORK, vol.29, no.2, pp.52-58, 2018 (SCI-Expanded)

- LX. **Plantar melanoma is associated with certain poor prognostic histopathological factors, but not correlated with nodal involvement, recurrence, and worse survival.**  
Tas F., Erturk K.  
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol.20, no.5, pp.607-612, 2018 (SCI-Expanded)
- LXI. **Acral Lentiginous Melanoma Is Associated with Certain Poor Prognostic Histopathological Factors but May Not be Correlated with Nodal Involvement, Recurrence, and a Worse Survival**  
Tas F., Erturk K.  
PATHOBIOLOGY, vol.85, no.4, pp.227-231, 2018 (SCI-Expanded)
- LXII. **Neurotropism as a prognostic factor in cutaneous melanoma patients.**  
Tas F., Erturk K.  
Neoplasma, vol.65, no.2, pp.304-308, 2018 (SCI-Expanded)
- LXIII. **Anemia in Cutaneous Malignant Melanoma: Low Blood Hemoglobin Level is Associated with Nodal Involvement, Metastatic Disease, and Worse Survival**  
Tas F., Erturk K.  
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, vol.70, no.2, pp.236-240, 2018 (SCI-Expanded)
- LXIV. **Digital clubbing as a first clinical presentation of pulmonary metastases in cutaneous melanoma**  
Tas F., Erturk K.  
POSTGRADUATE MEDICINE, vol.130, no.2, pp.278-279, 2018 (SCI-Expanded)
- LXV. **Cutaneous Melanoma in Association With Ichthyosis Vulgaris**  
Tas F., Erturk K., DEMİRKESEN C., Goktay F.  
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, vol.39, no.8, pp.630, 2017 (SCI-Expanded)
- LXVI. **Scalp melanoma is associated with high mitotic rate and is a poor prognostic factor for recurrence and outcome**  
Tas F., Erturk K.  
MELANOMA RESEARCH, vol.27, no.4, pp.387-390, 2017 (SCI-Expanded)
- LXVII. **Clinical Significance of Serum Ykl-40 (Chitinase-3-Like-1 Protein) as a Biomarker in Melanoma: an Analysis of 112 Turkish Patients**  
Erturk K., Tas F., Serilmez M., Bilgin E., Yasasever V.  
Asian Pacific journal of cancer prevention : APJCP, vol.18, pp.1383-1387, 2017 (SCI-Expanded)
- LXVIII. **Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors**  
Tas F., Erturk K.  
MELANOMA RESEARCH, vol.27, no.2, pp.134-139, 2017 (SCI-Expanded)
- LXIX. **Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma**  
Afsar C. U., Karabulut M., Karabulut S., Alis H., Gonenc M., Dagoglu N., Serilmez M., Tas F.  
JOURNAL OF INFECTION AND CHEMOTHERAPY, no.4, pp.196-200, 2017 (SCI-Expanded)
- LXX. **Clinical Significance of Circulating Serum Cellular Heat Shock Protein 90 (HSP90) Level in Patients with Cutaneous Malignant Melanoma**  
Tas F., Bilgin E., Erturk K., Duranyıldız D.  
Asian Pacific journal of cancer prevention : APJCP, vol.18, pp.599-601, 2017 (SCI-Expanded)
- LXXI. **Histological lymphovascular invasion is associated with nodal involvement, recurrence, and survival in patients with cutaneous malignant melanoma**  
Tas F., Erturk K.  
INTERNATIONAL JOURNAL OF DERMATOLOGY, vol.56, no.2, pp.166-170, 2017 (SCI-Expanded)
- LXXII. **Assessment of Anxiety and Depression Status in Turkish Cutaneous Melanoma Patients**  
Tas F., Karabulut S., Guveli H., Kurul S., Erturk K., Guveli M., Kinik H.  
Asian Pacific journal of cancer prevention : APJCP, vol.18, pp.369-373, 2017 (SCI-Expanded)
- LXXIII. **SERUM INTERLEUKIN-32 (IL-32) LEVELS MAY HAVE DIAGNOSTIC AND PROGNOSTIC ROLES IN**

## **PATIENTS WITH PANCREATIC ADENOCARCINOMA**

Karabulut M., Afsar C. U., Karabulut S., Peker K. D., Gemici E., Dagoglu N., Karaman S., Yasasever C. T., Tas F.  
ACTA MEDICA MEDITERRANEA, no.4, pp.613-619, 2017 (SCI-Expanded)

- LXXIV. **Tumor Infiltrating Lymphocytes (TILs) May be Only an Independent Predictor of Nodal Involvement but not for Recurrence and Survival in Cutaneous Melanoma Patients**  
Tas F., Erturk K.  
CANCER INVESTIGATION, vol.35, no.8, pp.501-505, 2017 (SCI-Expanded)
- LXXV. **Presence of histological regression as a prognostic factor in cutaneous melanoma patients.**  
Tas F., Erturk K.  
Melanoma research, vol.26, pp.492-6, 2016 (SCI-Expanded)
- LXXVI. **Clinical significance of serum claudin-1 levels in melanoma patients**  
Tas F., Bilgin E., Erturk K., Duranyildiz D.  
MELANOMA RESEARCH, vol.26, no.4, pp.377-381, 2016 (SCI-Expanded)
- LXXVII. **Serum leptin levels may have diagnostic and predictive roles in patients with pancreatic adenocarcinoma treated with gemcitabine-based chemotherapy.**  
Karabulut S., AFSAR C. U., KARABULUT M., ALIS H., Erturk K., Karaman S., KONES O., Bilgin E., Tas F.  
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.21, no.4, pp.895-902, 2016 (SCI-Expanded)
- LXXVIII. **Zosteriform type in-transit metastasis of melanoma**  
Tas F.  
INDIAN JOURNAL OF MEDICAL RESEARCH, vol.143, pp.143, 2016 (SCI-Expanded)
- LXXIX. **Clinical significance of serum caveolin-1 levels in melanoma patients**  
Tas F., Karabulut S., Yasasever C. T., Duranyildiz D.  
INTERNATIONAL JOURNAL OF DERMATOLOGY, vol.55, no.5, pp.558-562, 2016 (SCI-Expanded)
- LXXX. **Same Chemotherapy Regimen Leads to Different Myelotoxicity in Different Malignancies: A Comparison of Chemotherapy-Associated Myelotoxicity in Patients With Advanced Ovarian and Non-Small-Cell Lung Cancer.**  
Tas F., Yildiz I., Kilic L., Ciftci R., Keskin S., Sen F.  
American journal of therapeutics, vol.23, no.3, 2016 (SCI-Expanded)
- LXXXI. **Majority of the most-cited articles on cutaneous malignant melanoma are published in non-dermatology/melanoma specialized journals.**  
Tas F.  
Journal of cancer research and therapeutics, vol.12, pp.612-5, 2016 (SCI-Expanded)
- LXXXII. **Is it solitary plasmacytoma or nonsecretory myeloma? A must-be-solved dilemma?**  
Erturk K., Tastekin D., Gundogdu G., Tas F., Vatansever S.  
BIOMEDICINE & PHARMACOTHERAPY, vol.77, pp.27-29, 2016 (SCI-Expanded)
- LXXXIII. **Exacerbation of psoriasis induced by interferon-alpha treatment for melanoma**  
Tas F., Atsu N.  
CUTANEOUS AND OCULAR TOXICOLOGY, vol.35, no.1, pp.83-84, 2016 (SCI-Expanded)
- LXXXIV. **Pankreas Adenokanserli Hastalarda Serum Ekstrasellüler Matriks Proteinlerinin Prognostik ve Prediktif Değerinin Araştırılması**  
KARABULUT S., KARABULUT M., ALIS H., DAĞOĞLU N., TAMBAŞ M., KAPA S., ORAN E., OĞUZ SOYDİNÇ H., TAŞ F.  
Bakırköy Tıp Dergisi, vol.12, no.1, pp.24-32, 2016 (SCI-Expanded)
- LXXXV. **Clinical significance of serum protease activated receptor1 levels in patients with lung cancer**  
Erturk K., Tastekin D., Bilgin E., Tas F., Disci R., Duranyildiz D.  
European Review for Medical and Pharmacological Sciences, vol.20, no.2, pp.243-249, 2016 (SCI-Expanded)
- LXXXVI. **CIRCULATING MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHA (MIP1-A) AS A POTENTIAL BIOMARKER FOR THE DIAGNOSIS OF PATIENTS WITH PANCREATIC ADENOCARCINOMA**  
Karabulut S., Afsar C. U., Karabulut M., Alis H., Binboga S., Ozkara I. O., Karaca F., Bilgin E., Tas F.  
ACTA MEDICA MEDITERRANEA, vol.32, no.4, pp.1035-1040, 2016 (SCI-Expanded)
- LXXXVII. **Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients**

**with gastric cancer**

Tas F., Karabulut S., Serilmez M., KARABULUT M., Duranyildiz D.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.77, no.1, pp.127-131, 2016 (SCI-Expanded)

**LXXXVIII. Plasma homocysteine, folate and vitamin B12 levels in patients with lung cancer.**

Tastekin D., Erturk K., Bozbey H. U., Olmuscelik O., Kiziltan H., Tuna S., Tas F.

Experimental oncology, vol.37, pp.218-22, 2015 (SCI-Expanded)

**LXXXIX. Tongue metastasis of melanoma**

Tas F., Karabulut S., Yegen G., Onder S., Ciftci R.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.11, no.3, 2015 (SCI-Expanded)

**XC. Clinical significance of serum interleukin-18 (IL-18) levels in patients with gastric cancer**

Tas F., Yasasever C. T., Karabulut S., Tastekin D., Duranyildiz D.

BIOMEDICINE & PHARMACOTHERAPY, vol.70, pp.19-23, 2015 (SCI-Expanded)

**XCI. Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer.**

Tas F., Yasasever C. T., Karabulut S., Tastekin D., Duranyildiz D.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol.36, no.3, pp.2097-103, 2015 (SCI-Expanded)

**XCII. Circulating annexin A2 as a biomarker in gastric cancer patients: Correlation with clinical variables**

Tas F., Yasasever C. T., Karabulut S., Tastekin D., Duranyildiz D.

Biomedicine and Pharmacotherapy, vol.69, pp.237-241, 2015 (SCI-Expanded)

**XCIII. Clinical significance of serum epidermal growth factor receptor (EGFR) levels in patients with breast cancer**

Tas F., Bilgin E., Karabulut S., Duranyildiz D.

CYTOKINE, vol.71, no.1, pp.66-70, 2015 (SCI-Expanded)

**XCIV. Combination of Capecitabine and Phenytoin May Cause Phenytoin Intoxication: A Case Report**

Ciftci R., Tas F., Karabulut S., CIFTCI S.

AMERICAN JOURNAL OF THERAPEUTICS, vol.22, no.1, 2015 (SCI-Expanded)

**XCV. D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients.**

Kilic L., Yildiz I., Sen F. K., ERDEM M. G., Serilmez M., Keskin S., Ciftci R., Karabulut S., ORDU C., Duranyildiz D., et al.

Cancer biomarkers : section A of Disease markers, vol.15, no.4, pp.405-11, 2015 (SCI-Expanded)

**XCVI. Clinical significance of serum epithelial cell adhesion molecule (EPCAM) levels in patients with lung cancer**

Tas F., Karabulut S., Duranyildiz D.

MOLECULAR AND CELLULAR BIOCHEMISTRY, vol.396, pp.307-312, 2014 (SCI-Expanded)

**XCVII. Clinical significance of serum fibronectin and vitronectin levels in melanoma patients**

Tas F., Karabulut S., Bilgin E., Tastekin D., Duranyildiz D.

MELANOMA RESEARCH, vol.24, no.5, pp.475-479, 2014 (SCI-Expanded)

**XCVIII. Clinical significance of serum M30 and M65 levels in patients with breast cancer**

Tas F., Karabulut S., Yildiz I., Duranyildiz D.

BIOMEDICINE & PHARMACOTHERAPY, vol.68, no.8, pp.1135-1140, 2014 (SCI-Expanded)

**XCIX. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with breast cancer**

Tas F., Karabulut S., Bilgin E., Tastekin D., Duranyildiz D.

TUMOR BIOLOGY, vol.35, no.9, pp.9303-9309, 2014 (SCI-Expanded)

**C. The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer**

Karabulut S., Tas F., Tastekin D., KARABULUT M., Yasasever C., Ciftci R., Guveli M., Fayda M., Vatansever S., Serilmez M., et al.

TUMOR BIOLOGY, vol.35, no.9, pp.8849-8860, 2014 (SCI-Expanded)

**CI. The Behavior of Turkish Cancer Patients in Fasting During the Holy Month of Ramadan**

Tas F., Karabulut S., Ciftci R., Yildiz I., Keskin S., Kilic L., Disci R.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.44, no.8, pp.705-710, 2014 (SCI-Expanded)

- CII. **Serum levels of vascular cell adhesion molecule-1 (VCAM-1) may have diagnostic, predictive, and prognostic roles in patients with lung cancer treated with platinum-based chemotherapy**  
Tas F., Karabulut S., Bilgin E., Duranyildiz D.  
TUMOR BIOLOGY, vol.35, no.8, pp.7871-7875, 2014 (SCI-Expanded)
- CIII. **Clinical significance of serum tenascin-C levels in breast cancer**  
Tastekin D., Tas F., Karabulut S., Duranyildiz D., Serilmez M., Guveli M., Vatansever S.  
TUMOR BIOLOGY, vol.35, no.7, pp.6619-6625, 2014 (SCI-Expanded)
- CIV. **Clinical significance of serum tenascin-c levels in epithelial ovarian cancer**  
Didem T., Faruk T., Senem K., Derya D., Murat S., Murat G., OZNUR K.  
TUMOR BIOLOGY, vol.35, no.7, pp.6777-6782, 2014 (SCI-Expanded)
- CV. **Serum transforming growth factor-beta 1 (TGF-beta 1) levels have diagnostic, predictive, and possible prognostic roles in patients with melanoma**  
Tas F., Karabulut S., Yasasever C., Duranyildiz D.  
TUMOR BIOLOGY, vol.35, no.7, pp.7233-7237, 2014 (SCI-Expanded)
- CVI. **Clinical significance of serum ADP-ribosylation and NAD glycohydrolase activity in patients with colorectal cancer.**  
Varol B., ÇOŞKUN Ö., Karabulut S., SERIN K. R., Asoglu O., Albeniz I., Tas F., Nurten R.  
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol.35, no.6, pp.5575-82, 2014 (SCI-Expanded)
- CVII. **Coagulation tests show significant differences in patients with breast cancer**  
Tas F., Kilic L., Duranyildiz D.  
TUMOR BIOLOGY, vol.35, no.6, pp.5985-5992, 2014 (SCI-Expanded)
- CVIII. **Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy**  
Tas F., Karabulut S., Ciftci R., Sen F., Sakar B., Disci R., Duranyildiz D.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.73, no.6, pp.1163-1171, 2014 (SCI-Expanded)
- CIX. **An analysis of the most-cited research papers on oncology: which journals have they been published in?**  
Tas F.  
TUMOR BIOLOGY, vol.35, no.5, pp.4645-4649, 2014 (SCI-Expanded)
- CX. **Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on determination of epithelial ovarian carcinoma?**  
Karabulut S., Aksit E., Tas F., Ciftci R., Aydinler A., Yildiz I., Keskin S., Eralp Y., Yasasever C. T., Vatansever S., et al.  
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol.35, no.5, pp.4323-9, 2014 (SCI-Expanded)
- CXI. **Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer**  
Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.  
TUMOR BIOLOGY, vol.35, no.4, pp.3095-3102, 2014 (SCI-Expanded)
- CXII. **Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer**  
Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.  
TUMOR BIOLOGY, vol.35, no.4, pp.3125-3132, 2014 (SCI-Expanded)
- CXIII. **Serum levels of macrophage migration-inhibitory factor (MIF) have diagnostic, predictive and prognostic roles in epithelial ovarian cancer patients**  
Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.  
TUMOR BIOLOGY, vol.35, no.4, pp.3327-3331, 2014 (SCI-Expanded)
- CXIV. **Clinical significance of serum transforming growth factor-beta 1 (TGF-beta 1) levels in patients with epithelial ovarian cancer**

- Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.  
TUMOR BIOLOGY, vol.35, no.4, pp.3611-3616, 2014 (SCI-Expanded)
- CXV. **Recurrent gastric cancer presenting with both scrotal and facial skin metastases: a case report.**  
Tas F., Ciftci R., Buyukbabani N., Karabulut S.  
Journal of gastrointestinal cancer, vol.45, pp.96-9, 2014 (SCI-Expanded)
- CXVI. **Clinical significance of serum circulating insulin-like growth factor-1 (IGF-1) mRNA in hepatocellular carcinoma**  
Karabulut S., Duranyildiz D., Tas F., Gezer U., Akyuz F., Serilmez M., Ozgur E., Yasasever C. T., Vatansever S., Aykan N. F.  
TUMOR BIOLOGY, vol.35, no.3, pp.2729-2739, 2014 (SCI-Expanded)
- CXVII. **Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma**  
Karabulut S., Tas F., Akyuz F., Ormeci A., Serilmez M., Soydinc H. O., Vatansever S., Yasasever V.  
TUMOR BIOLOGY, vol.35, no.3, pp.2327-2333, 2014 (SCI-Expanded)
- CXVIII. **Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer**  
Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.73, no.3, pp.631-637, 2014 (SCI-Expanded)
- CXIX. **High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer**  
Ciftci R., Tas F., Yasasever C., Aksit E., Karabulut S., Sen F., Keskin S., Kilic L., Yildiz I., Bozbey H. U., et al.  
Tumor Biology, vol.35, no.7, pp.6941-6948, 2014 (SCI-Expanded)
- CXX. **Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma**  
Tas F., Karabulut S., Bilgin E., Sen F., Yildiz I., Tastekin D., Ciftci R., Duranyildiz D.  
TUMOR BIOLOGY, vol.34, no.6, pp.3529-3536, 2013 (SCI-Expanded)
- CXXI. **Clinical significance of coagulation assays in metastatic pancreatic adenocarcinoma.**  
Tas F., Karabulut S., Bilgin E., Kilic L., Ciftci R., Duranyildiz D.  
Journal of gastrointestinal cancer, vol.44, pp.404-9, 2013 (SCI-Expanded)
- CXXII. **Age is a prognostic factor affecting survival in lung cancer patients**  
Tas F., Ciftci R., Kilic L., Karabulut S.  
ONCOLOGY LETTERS, vol.6, no.5, pp.1507-1513, 2013 (SCI-Expanded)
- CXXIII. **The role of surgical methods in the treatment of anorectal malignant melanoma (AMM).**  
Keskin S., Tas F., Karabulut S., Yildiz I., Kiliç L., Ciftci R., Vatansever S.  
Acta chirurgica Belgica, vol.113, pp.429-33, 2013 (SCI-Expanded)
- CXXIV. **Clinical significance of serum M30 and M65 levels in melanoma**  
Tas F., Karabulut S., Serilmez M., Yildiz I., Sen F., Ciftci R., Duranyildiz D.  
MELANOMA RESEARCH, vol.23, no.5, pp.390-395, 2013 (SCI-Expanded)
- CXXV. **Performance status of patients is the major prognostic factor at all stages of pancreatic cancer**  
Tas F., Sen F., Odabas H., Kilic L., Keskin S., Yildiz I.  
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.18, no.5, pp.839-846, 2013 (SCI-Expanded)
- CXXVI. **Patellar metastasis of melanoma**  
Tas F., Keskin S.  
INDIAN JOURNAL OF MEDICAL RESEARCH, vol.138, pp.370, 2013 (SCI-Expanded)
- CXXVII. **Clinical and prognostic significance of coagulation assays in gastric cancer.**  
Tas F., Ciftci R., Kilic L., Serilmez M., Karabulut S., Duranyildiz D.  
Journal of gastrointestinal cancer, vol.44, pp.285-92, 2013 (SCI-Expanded)
- CXXVIII. **A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer**  
Yildiz I., Tas F., Kilic L., Sen F., Saip P., Eralp Y., Keskin S., Karabulut S., Ciftci R., Serilmez M., et al.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.72, no.2, pp.437-444, 2013 (SCI-Expanded)
- CXXIX. **Biweekly triplet chemotherapy with gemcitabine, cisplatin and vinorelbine for advanced chemotherapy naïve non-small cell lung cancer.**

Keskin S., Tas F., Ekenel M., Kilic L., Sen F., Yildiz I., Karabulut S., Ciftci R., Vatansever S.

Tumori, vol.99, no.4, pp.463-8, 2013 (SCI-Expanded)

- CXXX. **Oral etoposide as first-line therapy in the treatment of patients with advanced classic Kaposi's sarcoma (CKS): a single-arm trial (oral etoposide in CKS)**  
Tas F., Sen F., Keskin S., Kilic L.  
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, vol.27, no.6, pp.789-792, 2013 (SCI-Expanded)
- CXXXI. **Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy-naïve advanced non-small cell lung cancer**  
Tas F., Sen F., Guney N., Keskin S., Camlica H.  
ONCOLOGY LETTERS, vol.5, no.5, pp.1699-1703, 2013 (SCI-Expanded)
- CXXXII. **Clinical and prognostic significance of coagulation assays in lung cancer**  
Tas F., Kilic L., Serilmez M., Keskin S., Sen F., Duranyildiz D.  
RESPIRATORY MEDICINE, vol.107, no.3, pp.451-457, 2013 (SCI-Expanded)
- CXXXIII. **Clinical and Prognostic Significance of Coagulation Assays in Advanced Epithelial Ovarian Cancer**  
Tas F., Kilic L., Bilgin E., Keskin S., Sen F., Ciftci R., Yildiz I., Yasasever V.  
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol.23, no.2, pp.276-281, 2013 (SCI-Expanded)
- CXXXIV. **Adrenocortical carcinoma: clinicopathological features, prognostic factors and outcome.**  
Keskin S., Tas F., Vatansever S.  
Urologia internationalis, vol.90, no.4, pp.435-8, 2013 (SCI-Expanded)
- CXXXV. **Clinical and prognostic significance of coagulation assays in melanoma**  
Tas F., Ciftci R., Kilic L., Bilgin E., Keskin S., Sen F., Yildiz I., Yasasever V.  
MELANOMA RESEARCH, vol.22, no.5, pp.368-375, 2012 (SCI-Expanded)
- CXXXVI. **Age-specific incidence ratios of lung cancer (LC) in Turkey: LC in older people is increasing**  
Tas F., Keskin S.  
ARCHIVES OF GERONTOLOGY AND GERIATRICS, vol.55, no.2, pp.276-278, 2012 (SCI-Expanded)
- CXXXVII. **Age-specific incidence ratios of colorectal cancer (CRC) in Turkey: CRC in older people is increasing**  
Tas F., Keskin S.  
ARCHIVES OF GERONTOLOGY AND GERIATRICS, vol.55, no.2, pp.279-282, 2012 (SCI-Expanded)
- CXXXVIII. **Association of clinical and pathological variables with survival in thymoma.**  
Aydiner A., Toker A., Sen F., Bicakci E., Saglam E. K., Erus S., Eralp Y., Tas F., Oral E. N., Topuz E., et al.  
Medical oncology (Northwood, London, England), vol.29, no.3, pp.2221-8, 2012 (SCI-Expanded)
- CXXXIX. **Age-specific incidence ratios of breast cancer (BC) in Turkey: BC in older people is increasing**  
Tas F., Keskin S.  
ARCHIVES OF GERONTOLOGY AND GERIATRICS, vol.55, no.1, pp.112-115, 2012 (SCI-Expanded)
- CXL. **The major stressful life events and cancer: stress history and cancer**  
Tas F., Karalar U., Aliustaoglu M., Keskin S., Can G., Cinar F. E.  
MEDICAL ONCOLOGY, vol.29, no.2, pp.1371-1377, 2012 (SCI-Expanded)
- CXLI. **The roles of surgery and EMA/CO chemotherapy regimen in primary refractory and non-refractory gestational trophoblastic neoplasia**  
Aydiner A., Keskin S., Berkman S., Bengisu E., Ilhan H. R., Tas F., Topuz E.  
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.138, no.6, pp.971-977, 2012 (SCI-Expanded)
- CXLII. **Factors Influencing the Hormone Receptor and HER2 Levels in Breast Cancer: A Population-Based Analysis**  
Tas F.  
ONKOLOGIE, vol.35, no.3, pp.95-98, 2012 (SCI-Expanded)
- CXLIII. **Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors.**  
Tas F.  
Journal of oncology, vol.2012, pp.647684, 2012 (SCI-Expanded)
- CXLIV. **Classic Kaposi's sarcoma with colonic involvement: a rare presentation with successful treatment with oral etoposide.**

Tas F., Keskin S., Yegen G., Gozubuyukoglu N.

Journal of cancer research and therapeutics, vol.8, pp.112-3, 2012 (SCI-Expanded)

- CXLV. **Melanoma-associated hypopigmentation in association with locoregional relapse of melanoma**  
Tas F.  
SURGERY, vol.150, no.5, pp.1011-1012, 2011 (SCI-Expanded)
- CXLVI. **Induction Chemotherapy With Triweekly Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy With or Without Surgery in Stage III Non-Small-Cell Lung Cancer: A Phase II Study**  
Aydiner A., Sen F., SAGLAM E. K., Oral E. N., Eralp Y., Tas F., Toker A., Dilege S.  
CLINICAL LUNG CANCER, vol.12, no.5, pp.286-292, 2011 (SCI-Expanded)
- CXLVII. **Matrix metalloproteinase-9 decreased after chemotherapy in patients with non-small cell lung cancer**  
Ertan E., Soydinc H., YAZAR A., Ustuner Z., Tas F., Yasasever V.  
TUMORI, vol.97, no.3, pp.286-289, 2011 (SCI-Expanded)
- CXLVIII. **Age-specific Incidence Ratios in Malignant Melanoma in Turkey: Melanoma in Older People is Increasing**  
Tas F.  
ACTA DERMATO-VENEREOLOGICA, vol.91, no.3, pp.353-354, 2011 (SCI-Expanded)
- CXLIX. **Noncutaneous Melanoma Have Distinct Features from Each Other and Cutaneous Melanoma**  
Tas F., Keskin S., Karadeniz A., Dagoglu N., Sen F., Kilic L., Yildiz I.  
ONCOLOGY, no.5-6, pp.353-358, 2011 (SCI-Expanded)
- CL. **Cardiac involvement in melanoma: a case report and review of the literature.**  
Tas F., Mudun A., KIRMA C.  
Journal of cancer research and therapeutics, vol.6, no.3, pp.359-61, 2010 (SCI-Expanded)
- CLI. **Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer.**  
Topuz E., DERIN D., CAN G., Kuerklue E., Cinar S., Aykan F., Cevikbas A., Disci R., DURNA Z., Sakar B., et al.  
Investigational new drugs, vol.26, no.6, pp.567-72, 2008 (SCI-Expanded)
- CLII. **Statistical Interpretation of CA125 and Bcl-2 in Serum of Patients With Late Stage Ovarian Cancer**  
Camlica H., Duranyildiz D., Tas F., Yasasever V.  
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.31, no.6, pp.585-588, 2008 (SCI-Expanded)
- CLIII. **Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma**  
Tas F., Duranyildiz D., Oguz H., Camlica H., Yasasever V., Topuz E.  
MEDICAL ONCOLOGY, vol.25, no.4, pp.431-436, 2008 (SCI-Expanded)
- CLIV. **The contribution of countries and world regions in productivity of oncological publication.**  
Tas F.  
Annals of oncology : official journal of the European Society for Medical Oncology, vol.19, no.11, pp.1962-8, 2008 (SCI-Expanded)
- CLV. **Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases**  
Tas F., Duranyildiz D., Oguz H., Camlica H., Yasasever V., Topuz E.  
MEDICAL ONCOLOGY, vol.25, no.3, pp.346-349, 2008 (SCI-Expanded)
- CLVI. **Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer**  
Tas F., Derin D., Guney N., Aydiner A., Topuz E.  
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.13, no.4, pp.330-334, 2008 (SCI-Expanded)
- CLVII. **Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer**  
Tas F., Guney N., Derin D., Camlica H., Aydiner A., Topuz E.  
INVESTIGATIONAL NEW DRUGS, vol.26, no.4, pp.363-368, 2008 (SCI-Expanded)

- CLVIII. **Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer**  
Aydiner A., Tas F.  
TRIALS, vol.9, 2008 (SCI-Expanded)
- CLIX. **Temozolomide in combination with fotemustine in patients with metastatic melanoma**  
Tas F., Camlica H., Topuz E.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.62, no.2, pp.293-298, 2008 (SCI-Expanded)
- CLX. **Serum levels of intercellular adhesion molecule ICAM-1 and E-selectin in advanced stage non-small cell lung cancer**  
Guney N., Soydinc H. O., Derin D., Tas F., Camlica H., Duranyildiz D., Yasasever V., Topuz E.  
MEDICAL ONCOLOGY, vol.25, no.2, pp.194-200, 2008 (SCI-Expanded)
- CLXI. **A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer**  
Tas F., Guney N., Derin D., Aydiner A., Topuz E.  
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.13, no.2, pp.156-160, 2008 (SCI-Expanded)
- CLXII. **Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer**  
Tas F., Duranyildiz D., Soydinc H. O., Cicin I., Selam M., Uygun K., Disci R., Yasasever V., Topuz E.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.61, no.5, pp.721-725, 2008 (SCI-Expanded)
- CLXIII. **The role of serum vascular endothelial growth factor and matrix metalloproteinase-9 in predicting response to chemotherapy in patients with advanced nonsmall cell lung cancer**  
Yazar A., SOYDINC H., Ertan E., Yasasever V., Tas F.  
SOUTHERN MEDICAL JOURNAL, vol.101, no.3, pp.327-328, 2008 (SCI-Expanded)
- CLXIV. **Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer**  
Derin D., Soydinc H. O., Guney N., Tas F., Camlica H., Duranyildiz D., Yasasever V., Topuz E.  
LUNG CANCER, vol.59, no.2, pp.240-245, 2008 (SCI-Expanded)
- CLXV. **Macrophage migration inhibitory factor in cancer**  
Yasasever V., Camlica H., Duranyildiz D., Oguz H., Tas F., Dalay N.  
CANCER INVESTIGATION, vol.25, no.8, pp.715-719, 2007 (SCI-Expanded)
- CLXVI. **Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma**  
Tas F., Derin D., Guney N., Camlica H., Aydiner A., Topuz E.  
LUNG CANCER, vol.57, no.1, pp.79-83, 2007 (SCI-Expanded)
- CLXVII. **Pattern and outcome of admission to a medical oncology inpatient service**  
Tas F., ARGON A., Disci R., TOPUZ E.  
JOURNAL OF CANCER EDUCATION, vol.22, no.2, pp.80-85, 2007 (SCI-Expanded)
- CLXVIII. **The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer**  
Karagol H., Saip P., Uygun K., Caloglu M., Eralp Y., Tas F., Aydiner A., Topuz E.  
MEDICAL ONCOLOGY, vol.24, no.1, pp.39-43, 2007 (SCI-Expanded)
- CLXIX. **Serum IL-8 and IL-12 levels in breast cancer**  
Derin D., SOYDINC H. O., Güney N., Tas F., Çamlica H., Duranyıldız D., Yasasever V., Topuz E.  
MEDICAL ONCOLOGY, vol.24, no.2, pp.163-168, 2007 (SCI-Expanded)
- CLXX. **Malignant melanoma in Turkey: A single institution's experience on 475 cases**  
Tas F., Kurul S., Camlica H., Topuz E.  
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.12, pp.794-799, 2006 (SCI-Expanded)
- CLXXI. **Increased sister chromatid exchange frequency in young women with breast cancer and in their first-degree relatives.**  
Cefle K., Ucur A., Guney N., Ozturk S., Palanduz S., Tas F., Asoglu O., Bayrak A. G., Muslumanoglu M. E., Aydiner A.  
Cancer genetics and cytogenetics, vol.171, pp.65-7, 2006 (SCI-Expanded)
- CLXXII. **Sentinel lymph node biopsy for the staging of anal melanoma: Report of two cases**

Şanlı Y., Turkmen C., Kurul S., Tas F., Mudun A., Cantez S.

ANNALS OF NUCLEAR MEDICINE, vol.20, no.9, pp.629-631, 2006 (SCI-Expanded)

- CLXXIII. **Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients**

Tas F., Duranyıldız D., OĞUZ H., Çamlıca H., Yasasever V., Topuz E.

MELANOMA RESEARCH, vol.16, no.5, pp.405-411, 2006 (SCI-Expanded)

- CLXXIV. **Serum vascular endothelial growth factor (VEGF) and Bcl-2 levels in advanced stage non-small cell lung cancer**

Tas F., Duranyıldız D., OĞUZ H., Çamlıca H., Yasasever V., Topuz E.

CANCER INVESTIGATION, vol.24, no.6, pp.576-580, 2006 (SCI-Expanded)

- CLXXV. **Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer**

Tas F., DURANYILDIZ D., Oguz H., CAMLICA H., YASASEVER V., TOPUZ E.

CANCER INVESTIGATION, vol.24, no.5, pp.492-496, 2006 (SCI-Expanded)

- CLXXVI. **Penile metastasis of cutaneous malignant melanoma: a true hematogenous spread? Case report and review of the literature**

Kurul S., Aykan F., Tas F.

MELANOMA RESEARCH, vol.16, no.3, pp.259-261, 2006 (SCI-Expanded)

- CLXXVII. **Images in pathology. Tumor spreading along an incisional scar line.**

Tas F., Yavuz E.

International journal of surgical pathology, vol.14, no.2, pp.143, 2006 (SCI-Expanded)

- CLXXVIII. **Intermediate dose interferon alpha in adjuvant treatment for high-risk melanoma - A single institution's experience**

Tas F., Kurul S., Camlica H., Topuz E.

MEDICAL ONCOLOGY, vol.23, no.4, pp.471-477, 2006 (SCI-Expanded)

- CLXXIX. **The value of serum bcl-2 levels in advanced epithelial ovarian cancer.**

TAS F., DURANYILDIZ D., OGUZ H., CAMLICA H., Yasasever V., TOPUZ E.

Medical oncology (Northwood, London, England), vol.23, no.2, pp.213-7, 2006 (SCI-Expanded)

- CLXXX. **Serum and urine survivin levels in breast cancer**

Güney N., SOYDINE H., DEFIN D., Tas F., Çamlıca H., Duranyıldız D., Yasasever V., Topuz E.

MEDICAL ONCOLOGY, vol.23, no.3, pp.335-339, 2006 (SCI-Expanded)

- CLXXXI. **Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial.**

Tas F., Argon A., Camlica H., Topuz E.

Melanoma research, vol.15, no.6, pp.543-8, 2005 (SCI-Expanded)

- CLXXXII. **Different manifestations of malignant melanoma in the breast: a report of 12 cases and a review of the literature.**

Kurul S., Tas F., Buyukbabani N., Mudun A., Baykal C., Camlica H.

Japanese journal of clinical oncology, vol.35, no.4, pp.202-6, 2005 (SCI-Expanded)

- CLXXXIII. **Oxidative stress in breast cancer.**

Tas F., Hansel H., Belce A., Ilvan S., Argon A., Camlica H., Topuz E.

Medical oncology (Northwood, London, England), vol.22, no.1, pp.11-5, 2005 (SCI-Expanded)

- CLXXXIV. **Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma**

TAS F., DURANYILDIZ D., OGUZ H., DISCI R., KURUL S., Yasasever V., TOPUZ E.

MEDICAL ONCOLOGY, vol.22, no.1, pp.39-44, 2005 (SCI-Expanded)

- CLXXXV. **The value of serum Bcl-2 levels in advanced lung cancer patients**

TAS F., DURANYILDIZ D., OGUZ H., CAMLICA H., ORAL E., Yasasever V., TOPUZ E.

MEDICAL ONCOLOGY, vol.22, no.2, pp.139-143, 2005 (SCI-Expanded)

- CLXXXVI. **The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma**

TAS F., OGUZ H., ARGON A., DURANYILDIZ D., CAMLICA H., Yasasever V., TOPUZ E.

MEDICAL ONCOLOGY, vol.22, no.3, pp.241-246, 2005 (SCI-Expanded)

- CLXXXVII. **The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients.**  
TAS F., USTUNER Z., CAN G., ERALP Y., CAMLICA H., BASARAN M., KARAGOL H., SAKAR B., Disci R., TOPUZ E.  
Acta oncologica (Stockholm, Sweden), vol.44, no.2, pp.161-7, 2005 (SCI-Expanded)
- .LXXXVIII. **Apoptosis of lymphocytes in peripheral blood of patients with melanoma**  
TAS F., DURANYILDIZ D., ARGON A., GUZ H., CAMLICA H., Yasasever V., TOPUZ E.  
MEDICAL ONCOLOGY, vol.22, no.2, pp.177-181, 2005 (SCI-Expanded)
- CLXXXIX. **Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer**  
TAS F., DURANYILDIZ D., ARGON A., OGUZ H., CAMLICA H., Yasasever V., TOPUZ E.  
MEDICAL ONCOLOGY, vol.22, no.4, pp.353-358, 2005 (SCI-Expanded)
- CXC. **Serum bcl-2 and survivin levels in melanoma**  
TAS F., DURANYILDIZ D., ARGON A., OGUZ H., CAMLICA H., Yasasever V., TOPUZ E.  
MELANOMA RESEARCH, vol.14, no.6, pp.543-546, 2004 (SCI-Expanded)
- CXCI. **Successful palliative treatment of an inoperable giant squamous skin cancer: a case report.**  
Karadeniz A., Arslan M., Cizmeci O., Tas F.  
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.9, pp.313-6, 2004 (SCI-Expanded)
- CXCII. **Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma.**  
TAS F., Yasasever V., DURANYILDIZ D., CAMLICA H., USTUNER Z., AYDINER A., TOPUZ E.  
American journal of clinical oncology, vol.27, no.3, pp.225-8, 2004 (SCI-Expanded)
- CXCIII. **Massive and isolated metastases to spleen of uveal malignant melanoma.**  
Tas F., Ustuner Z., Buyukbabani N., Tenekeci N., Topuz E.  
Retina (Philadelphia, Pa.), vol.24, no.1, pp.170-2, 2004 (SCI-Expanded)
- CXCIV. **Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.**  
Tas F., Demir C., Camlica H., Ustuner Z., Topuz E.  
Medical oncology (Northwood, London, England), vol.21, no.3, pp.233-40, 2004 (SCI-Expanded)
- CXCV. **Granulosa cell tumor of the ovary: retrospective analysis of 45 cases.**  
Uygun K., Aydiner A., Saip P., Basaran M., Tas F., Kocak Z., Dincer M., Topuz E.  
American journal of clinical oncology, vol.26, no.5, pp.517-21, 2003 (SCI-Expanded)
- CXCVI. **Retrovesical soft-tissue metastasis of malignant thymoma: case report.**  
Tas F., Agan M., Tenekeci N., Topuz E.  
American journal of clinical oncology, vol.26, no.4, pp.366-8, 2003 (SCI-Expanded)
- CXCVII. **Phlebitis due to irinotecan.**  
Tas F., Karagol H., Karadeniz A. N., Topuz E.  
Clinical oncology (Royal College of Radiologists (Great Britain)), vol.15, no.3, pp.167, 2003 (SCI-Expanded)
- CXCVIII. **Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma.**  
Tas F., Camlica H., Kurul S., Aydiner A., Topuz E.  
Clinical oncology (Royal College of Radiologists (Great Britain)), vol.15, no.3, pp.132-5, 2003 (SCI-Expanded)
- CXCIX. **Detection of circulating melanoma cells by a two-marker polymerase chain reaction assay in relation to therapy.**  
Bitisik O., Camlica H., Duranyildiz D., Tas F., Kurul S., Dalay N.  
Journal of biochemistry and molecular biology, vol.36, no.2, pp.173-8, 2003 (SCI-Expanded)
- CC. **Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix.**  
Eralp Y., Saip P., Sakar B., Tas F., Aydiner A., Topuz E.  
European journal of gynaecological oncology, vol.24, pp.323-6, 2003 (SCI-Expanded)
- CCI. **Adjuvant intraperitoneal chemotherapy with cisplatin, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study.**  
Topuz E., Basaran M., Saip P., Aydiner A., Argon A., Sakar B., Tas F., Uygun K., Bugra D., Aykan N.  
American journal of clinical oncology, vol.25, no.6, pp.619-24, 2002 (SCI-Expanded)
- CCII. **Anemia in oncology practice: relation to diseases and their therapies.**

- Tas F., Eralp Y., Basaran M., Sakar B., Alici S., Argon A., Bulutlar G., Camlica H., Aydiner A., Topuz E.  
American journal of clinical oncology, vol.25, no.4, pp.371-9, 2002 (SCI-Expanded)
- CCIII. **Safety of paclitaxel in a patient with ovarian cancer and hyperbilirubinemia due to Rotor's syndrome.**  
Argon A., Aydiner A., Tas F., Saip P., Topuz E.  
Gynecologic oncology, vol.85, no.2, pp.362-4, 2002 (SCI-Expanded)
- CCIV. **Prognostic role of nm23 gene expression in patients with ovarian cancer.**  
Tas F., Tuzlali S., Aydiner A., Saip P., Salihoglu Y., Iplikci A., Topuz E.  
American journal of clinical oncology, vol.25, no.2, pp.164-7, 2002 (SCI-Expanded)
- CCV. **Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease.**  
Tas F., Aykan F., Alici S., Kaytan E., Aydiner A., Topuz E.  
American journal of clinical oncology, vol.24, no.6, pp.547-50, 2001 (SCI-Expanded)
- CCVI. **Prognostic significance of melanoma inhibiting activity levels in malignant melanoma.**  
Meral R., Duranyildiz D., Tas F., Camlica H., Yasasever V., Kurul S., Dalay N.  
Melanoma research, vol.11, no.6, pp.627-32, 2001 (SCI-Expanded)
- CCVII. **Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100): a phase II study.**  
Basaran M., Bavbek E., Sakar B., Eralp Y., Alici S., Tas F., Yaman F., Dogan O., Camlica H., Onat H.  
American journal of clinical oncology, vol.24, no.6, pp.570-5, 2001 (SCI-Expanded)
- CCVIII. **Circulating HER-2/NEU levels in patients with melanoma.**  
Eralp Y., Aydiner A., Toptani S., Tas F., Camlica H., Topuz E.  
CLINICAL CANCER RESEARCH, vol.7, no.11, 2001 (SCI-Expanded)
- CCIX. **Stevens-Johnson syndrome in a patient receiving anticonvulsant therapy during cranial irradiation.**  
Eralp Y., Aydiner A., Tas F., Saip P., Topuz E.  
American journal of clinical oncology, vol.24, no.4, pp.347-50, 2001 (SCI-Expanded)
- CCX. **Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer.**  
Tas F., Aydiner A., Demir C., Topuz E.  
American journal of clinical oncology, vol.24, no.4, pp.376-8, 2001 (SCI-Expanded)
- CCXI. **Measurement of serum CA 19-9 may be more valuable than CEA in prediction of recurrence in patients with gastric cancer.**  
TAS F., AYKAN F., AYDINER A., YASASEVER V., TOPUZ E.  
American journal of clinical oncology, vol.24, no.2, pp.148-9, 2001 (SCI-Expanded)
- CCXII. **5-fluorouracil-induced balanitis in a patient with oesophageal carcinoma.**  
Tas F., Basaran M., Aydiner A., Eralp Y., Topuz E.  
Clinical oncology (Royal College of Radiologists (Great Britain)), vol.13, no.3, pp.170-1, 2001 (SCI-Expanded)
- CCXIII. **The efficacy of combination chemotherapy including intraperitoneal cisplatin and mitoxantrone with intravenous ifosfamide in patients with FIGO stage I C ovarian carcinoma.**  
Topuz E., Eralp Y., Saip P., Aydiner A., Taş F., Saliho Y., Salihoğlu Y., Berkman S., Bengisu E.  
European journal of gynaecological oncology, vol.22, pp.70-3, 2001 (SCI-Expanded)
- CCXIV. **The efficacy of combination chemotherapy including intraperitoneal cisplatin and mitoxantrone with intravenous ifosfamide in patients with FIGO stage IC ovarian carcinoma**  
Topuz E., Eralp Y., Saip P., Aydiner A., Tas F., Salihoglu Y., Berkman S., Bengisu E.  
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.22, no.1, pp.70-73, 2001 (SCI-Expanded)
- CCXV. **The role of chemotherapy in malignant mixed mullerian tumors of the female genital tract.**  
Topuz E., Eralp Y., Aydiner A., Saip P., Taş F., Yavuz E., Salihoğlu Y.  
European journal of gynaecological oncology, vol.22, pp.469-72, 2001 (SCI-Expanded)
- CCXVI. **Hypertrophic osteoarthropathy associated with docetaxel treatment.**  
Tas F., Aydiner A., Tenekeci N., Karadeniz A. N., Sakar B., Topuz E.  
Clinical oncology (Royal College of Radiologists (Great Britain)), vol.13, no.2, pp.145-6, 2001 (SCI-Expanded)
- CCXVII. **Angiogenesis and p53 protein expression in breast cancer - Prognostic roles and interrelationships**

TAS F., YAVUZ E., AYDINER A., SAİP P., DISCI R., IPLIKCI A., TOPUZ E.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.23, no.6, pp.546-553, 2000 (SCI-Expanded)

- CCXVIII. **Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.**

Tas F., Aydiner A., Topuz E., YASASEVER V., Karadeniz A. N., Saip P. M.

Journal of experimental & clinical cancer research : CR, vol.19, no.4, pp.477-81, 2000 (SCI-Expanded)

- CCXIX. **Multiple primary neoplasms at a single institution: differences between synchronous and metachronous neoplasms.**

Aydiner A., Karadeniz A. N., Uygun K., Tas S., Tas F., Disci R., Topuz E.

American journal of clinical oncology, vol.23, no.4, pp.364-70, 2000 (SCI-Expanded)

- CCXX. **Celsite (R) port and catheter as an intraperitoneal access device in the treatment of ovarian cancer**

TOPUZ E., Salihoglu Y., AYDINER A., Saip P. M., TAS F., SOZEN T., BERKMAN S., BENGISU E.

JOURNAL OF SURGICAL ONCOLOGY, vol.74, no.3, pp.223-226, 2000 (SCI-Expanded)

- CCXXI. **Celsite port and catheter as an intraperitoneal access device in the treatment of ovarian cancer.**

Topuz E., Salihoglu Y., Aydiner A., Saip P., Tas F., Sozen T., Berkman S., Bengisu E.

Journal of surgical oncology, vol.74, pp.223-6, 2000 (SCI-Expanded)

- CCXXII. **Serum levels of the soluble adhesion molecules in patients with malignant melanoma**

YASASEVER F. V., TAŞ F., DURANYILDIZ H. D., Çamlıca H., KURUL S., DALAY M. N.

PATHOLOGY & ONCOLOGY RESEARCH, vol.6, no.1, pp.42-45, 2000 (SCI-Expanded)

- CCXXIII. **The roles of chemotherapy and surgery in gastric carcinoma and the influence of prognostic factors on survival.**

Tas F., Aykan N., Aydiner A., Uygun K., Basaran M., Camlica H., Topuz E.

American journal of clinical oncology, vol.23, no.1, pp.53-7, 2000 (SCI-Expanded)

- CCXXIV. **Crossover clinical study comparing the pharmacokinetics of etoposide (75 mg) administered as 25-mg capsules three times a day versus once a day.**

Aydiner A., Koyuncu H., Tas F., Topuz E., Disci R.

International journal of clinical pharmacology research, vol.20, pp.21-30, 2000 (SCI-Expanded)

- CCXXV. **The role of chemotherapy in malignant mixed mullerian tumors of the female genital tract.**

TOPUZ E., ERALP Y., AYDINER A., Saip P. M., TAS F., YAVUZ E., Salihoglu Y.

ANNALS OF ONCOLOGY, vol.11, pp.87-88, 2000 (SCI-Expanded)

- CCXXVI. **Chemotherapy in advanced breast carcinoma: Efficacy of primary and secondary or tertiary docetaxel use.**

Aydiner A., Topuz E., Argon A., Saip P., Tas F., Eralp Y., Kardas H.

ANNALS OF ONCOLOGY, vol.11, pp.37, 2000 (SCI-Expanded)

- CCXXVII. **Correlations of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer.**

TOPUZ E., AYDINER A., Saip P. M., ERALP Y., TAS F., Salihoglu Y., TENEKECI N.

European journal of gynaecological oncology, vol.21, no.6, pp.599-602, 2000 (SCI-Expanded)

- CCXXVIII. **Long term results and prognostic factors of granulosa cell tumors of the ovary.**

SAİP P. M., Uygun K., Topuz E., BAŞARAN M., TAŞ F., AYDINER A., Aslay I., Dincer M.

ANNALS OF ONCOLOGY, vol.11, pp.87, 2000 (SCI-Expanded)

- CCXXIX. **Adjuvant intraperitoneal chemotherapy with cisplatin, mitoxantrone, 5-fluorouracil and calcium folinate in stage II-III gastric cancer**

Topuz E., Aykan F., Basaran M., Uygun K., Tas F., Sakar B., Saip P., Bugra D., Camlica H., Aydiner A.

EUROPEAN JOURNAL OF CANCER, vol.35, 1999 (SCI-Expanded)

- CCXXX. **Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer.**

Tas F., Aydiner A., Topuz E., Camlica H., Saip P., Eralp Y.

Acta oncologica (Stockholm, Sweden), vol.38, no.8, pp.1011-5, 1999 (SCI-Expanded)

- CCXXXI. **A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin,**

**and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group.**  
Icli F., Celik I., Aykan F., Uner A., Demirkazik A., Ozet A., Ozguroglu M., Tas F., Akbulut H., Firat D.  
Cancer, vol.83, no.12, pp.2475-80, 1998 (SCI-Expanded)

CCXXXII. **Clinical efficacy of diazepam in prophylaxis of acute and delayed emesis induced by cisplatin based chemotherapy. A prospective randomised trial**  
Saip P., Onat H., Basaran M., Tas F., Demir C., Uygun K., Topuz E.  
ANNALS OF ONCOLOGY, vol.9, pp.146, 1998 (SCI-Expanded)

CCXXXIII. **Oral etoposide in patients with small cell lung cancer**  
Topuz E., Tas F., Aydiner A., Demir C., Saip P., Salepci T., Karadeniz A., Erturk N.  
EUROPEAN JOURNAL OF CANCER, vol.33, pp.1072, 1997 (SCI-Expanded)

CCXXXIV. **ECG and blood pressure changes during the 6-hours paclitaxel infusion**  
Saip P., Basaran M., Aydimer A., Erdogan O., Salepci T., Tas F., Topuz E.  
EUROPEAN JOURNAL OF CANCER, vol.33, pp.247, 1997 (SCI-Expanded)

CCXXXV. **Oral etoposide in patients (pts) with Kaposi's sarcoma (KS)**  
Aydiner A., Tas F., Saip P., Karadeniz A., Demir C., Salepci T., Topuz E.  
EUROPEAN JOURNAL OF CANCER, vol.33, pp.1178, 1997 (SCI-Expanded)

## Articles Published in Other Journals

- I. **A Modified H-index Calculated Using the Duration of Professional Experience and the Author's Significant Contribution to Publications.**  
Tas F., Erturk K.  
Cureus, vol.16, no.1, 2024 (ESCI)
- II. **Intraabdominal splenosis due to traffic accident**  
TAŞ F., KIZILDAĞ YIRGIN İ.  
TRAUMA-ENGLAND, no.3, pp.275-276, 2023 (ESCI)
- III. **Widespread finger skin metastases of melanoma**  
Tas F., Erturk K.  
CLINICAL CASE REPORTS, vol.6, no.2, pp.448-449, 2018 (ESCI)
- IV. **Significance of serum neural precursor cell-expressed developmentally downregulated protein 9 in melanoma**  
Erturk K., Tas F., Serilmez M., Bilgin E., Duranyıldız D.  
MOLECULAR AND CLINICAL ONCOLOGY, vol.8, no.1, pp.204-208, 2018 (ESCI)
- V. **Significant Neutrophilic Emperipolesis in Squamous Cell Carcinoma**  
Tetikurt S., Tas F., Emre F., Ozsoy S., Bilece Z. T.  
CASE REPORTS IN ONCOLOGICAL MEDICINE, 2018 (ESCI)
- VI. **Effect of biology on the outcome of female melanoma patients**  
Erturk K., Tas F.  
MOLECULAR AND CLINICAL ONCOLOGY, vol.7, no.6, pp.1093-1100, 2017 (ESCI)
- VII. **Elevated erythrocyte sedimentation rate is associated with metastatic disease and worse survival in patients with cutaneous malignant melanoma**  
Tas F., Erturk K.  
MOLECULAR AND CLINICAL ONCOLOGY, vol.7, no.6, pp.1142-1146, 2017 (ESCI)
- VIII. **Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival**  
Tas F., Erturk K.  
MOLECULAR AND CLINICAL ONCOLOGY, vol.7, no.6, pp.1083-1088, 2017 (ESCI)
- IX. **Clinical significance of serum omentin-1 levels in patients with pancreatic adenocarcinoma**  
Karabulut S., Afsar C. U., Karabulut M., Alis H., Bozkurt M. A., Aydogan F., Serilmez M., Tas F.  
BBA CLINICAL, vol.6, pp.138-142, 2016 (ESCI)

- X. **Clinical significance of serum protease-activated receptor 1 (PAR1) level in patients with breast cancer**  
Ciftci R., Taş F., Bilgin E., Keskin S., Yildiz I., Duranyildiz D., Saip P., Karanlık H., Vatansever S.  
Journal of Oncological Science, vol.2, no.1, pp.7-11, 2016 (Peer-Reviewed Journal)
- XI. **Clinical significance of serum laminin and type-IV collagen levels in cutaneous melanoma patients**  
Tas F., Bilgin E., Karabulut S., Duranyildiz D.  
MOLECULAR AND CLINICAL ONCOLOGY, vol.5, no.1, pp.195-200, 2016 (ESCI)
- XII. **Clinical Significance of Serum Galectin-3 Levels in Gastric Cancer Patients.**  
Tas F., Bilgin E., Tastekin D., Erturk K., Duranyildiz D.  
Journal of gastrointestinal cancer, vol.47, pp.182-6, 2016 (Scopus)
- XIII. **Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma**  
Tas F., Bilgin E., Karabulut S., Erturk K., Duranyildiz D.  
BBA CLINICAL, vol.5, pp.166-169, 2016 (ESCI)
- XIV. **Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer**  
Tas F., Bilgin E., Tastekin D., Erturk K., Duranyildiz D.  
BIOMEDICAL REPORTS, vol.4, no.5, pp.609-614, 2016 (ESCI)
- XV. **Pankreas Adenokanserli Hastalarda Serum Transforme Edici Büyüme Faktör Beta-1 (TGF B1) Düzeyleri**  
KARABULUT S., KARABULUT M., USUL AFŞAR Ç., ALIŞ H., DAĞOĞLU SAKİN R. N., AKARSU C., ERTÜRK K., BİLGİN DOĞRU E., TAŞ F.  
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, vol.12, no.1, pp.24-32, 2016 (Peer-Reviewed Journal)
- XVI. **Clinical significance of serum laminin levels in patients with lung cancer**  
Tas F., Bilgin E., Tastekin D., Erturk K., Duranyildiz D.  
BIOMEDICAL REPORTS, vol.4, no.4, pp.485-488, 2016 (ESCI)
- XVII. **Levels of serum fibronectin as a biomarker in gastric cancer patients: Correlation with clinical diagnosis and outcome**  
Tas F., Bilgin E., Karabulut S., Tastekin D., Duranyildiz D.  
MOLECULAR AND CLINICAL ONCOLOGY, vol.4, no.4, pp.655-659, 2016 (ESCI)
- XVIII. **Clinical significance of serum protease-activated receptor-1 levels in gastric cancer patients**  
Tas F., Karabulut S., Tastekin D., Duranyildiz D.  
BIOMEDICAL REPORTS, vol.4, no.4, pp.489-492, 2016 (ESCI)
- XIX. **Pankreas adenokarsinomlu hastalarda serum transforme edici büyüme factor beta 1 TGF B1 düzeyleri**  
KARABULUT S., KARABULUT M., AFŞAR USUL Ç., ALIŞ H., DAĞOĞLU N., AKARSU C., ERTÜRK K., BİLGİN E., TAŞ F.  
İstanbul Tıp Fakültesi Dergisi, vol.79, no.1, pp.9-15, 2016 (Peer-Reviewed Journal)
- XX. **SERUM TRANSFORMING GROWTH FACTOR BETA 1 (TGF-B1) LEVELS IN PANCREATIC ADENOCARCINOMA PATIENTS**  
Karabulut S., Karabulut M., Usul Afsar C., Alis H., Dagoglu N., Akarsu C., Erturk K., Bilgin E., Tas F.  
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, no.1, pp.9-15, 2016 (ESCI)
- XXI. **Pankreas adenokanserli hastalarda serum ekstrasellülmatriks proteinlerininprognostik ve prediktif değerinin araştırılması**  
KARABULUT S., KARABULUT M., ALIŞ H., DAĞOĞLU R. N., TAMBAŞ M., KAPAN S., ORAN E., OĞUZ H., TAŞ F.  
MEDICAL JOURNAL OF BAKIRKOY, vol.12, no.1, pp.24-32, 2016 (Scopus)
- XXII. **The predictive and prognostic value evaluation of serum extracellular matrix proteins levels in patients with pancreas adenocarcinoma**  
Karabulut S., KARABULUT M., ALIS H., Dagoglu N., Tambas M., KAPAN S., ORAN E., Oguz H., Tas F.  
MEDICAL JOURNAL OF BAKIRKOY, no.1, pp.24-32, 2016 (ESCI)
- XXIII. **Is serum tenascin-C level potential biomarker in pancreatic adenocarcinoma?**  
Karabulut S., KARABULUT M., ALIS H., Tambas M., KAPAN S., KONES O., Karaman S., Serilmez M., Tas F.

MEDICAL JOURNAL OF BAKIRKOY, vol.12, no.2, pp.76-82, 2016 (ESCI)

**XXIV. CLINICAL SIGNIFICANCE OF CIRCULATING PROINFLAMMATORY CYTOKINE LEVELS IN PATIENTS WITH PANCREATIC ADENOCARCINOMA**

Karabulut S., Karabulut M., Afsar C. U., Alis H., Guveli M. E., Unsal M. G., Aydogan F., Bilgin E., Tas F.  
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, vol.78, no.4, pp.102-109, 2015 (ESCI)

**XXV. Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival.**

Tas F., Sen F., Keskin S., Kilic L., Yildiz I.  
Molecular and clinical oncology, vol.1, pp.788-792, 2013 (ESCI)

**XXVI. Mucosal melanoma in the head and neck region: different clinical features and same outcome to cutaneous melanoma.**

Tas F., Keskin S.  
ISRN dermatology, vol.2013, pp.586915, 2013 (Peer-Reviewed Journal)

**XXVII. Küçük Hücreli Akciğer Kanseri Anjiogenik Faktörler (VEGF, VEGFR-1, VEGFR-2)**

OĞUZ SOYDİNC H., DURANYILDIZ D., BILGIN E., TAŞ F., YASASEVER V.  
TÜRK ONKOLOJİ DERGİSİ, vol.27, no.2, pp.55-61, 2012 (Scopus)

**XXVIII. Angiogenic factors in small veil lung cancer (VEGF, VEGFR-1, VEGFR-2)**

OĞUZ SOYDİNC H., DURANYILDIZ H. D., Bilgin E., TAŞ F., Yasasever V.  
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.27, no.2, pp.55-61, 2012 (ESCI)

**XXIX. Primary mucosal malignant melanoma of the nasopharynx: two case reports**

Karadeniz A., Gurocak S., Biliciler N., BAŞARAN M., TAŞ F.  
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.24, no.3, pp.131-137, 2009 (ESCI)

**XXX. Evre IV küçük hücreli dışı akciğer kanserinde serum vasküler endotelial büyüme faktörü ve Bcl-2 düzeyleri ve aralarındaki ilişki**

ERTAN E., OĞUZ SOYDİNC H., YAZAR A., ÖZGÜL A., TAŞ F., YASASEVER V., CAMLICA H., YILMAZ V.  
TÜRK ONKOLOJİ DERGİSİ, vol.22, no.2, pp.76-81, 2007 (Scopus)

**XXXI. The levels of serum vascular endothelial growth factor and Bcl-2 and association between them in stage IV non-small cell lung cancer**

Yazar E. E., OĞUZ SOYDİNC H., Yazar A., Ozgul A., TAŞ F., Yasasever V., Camlica H., Yilmaz V.  
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.22, no.2, pp.76-81, 2007 (ESCI)

**XXXII. Matriks Metalloproteinazlar ve Akciğer Kanseri**

OĞUZ H., Çamlıca H., DURANYILDIZ H. D., KAYTAN SAĞLAM E., TAŞ F., YASASEVER F. V., DALAY M. N., OĞUZ SOYDİNC H.  
TÜRK ONKOLOJİ DERGİSİ, vol.21, no.2, pp.53-56, 2006 (Peer-Reviewed Journal)

**XXXIII. Matrix metalloproteinases and lung cancer**

OĞUZ SOYDİNC H., Camlica H., DURANYILDIZ H. D., KAYTAN SAĞLAM E., TAŞ F., Yasasever V., Dalay N.  
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.21, no.2, pp.53-56, 2006 (ESCI)

**XXXIV. MALIGNANT MELANOMA AND SURVIVIN**

Oguz H., DURANYILDIZ H. D., Camlica H., TAŞ F., Yasasever V., Topuz E.  
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.20, no.1, pp.27-29, 2005 (ESCI)

**XXXV. Malign Melanom ve Survivin**

OĞUZ SOYDİNC H., DURANYILDIZ D., CAMLICA H., TAŞ F., YASASEVER V., TOPUZ E.  
TÜRK ONKOLOJİ DERGİSİ, vol.20, no.1, pp.27-29, 2005 (ESCI)

**XXXVI. Malign Melanomalı Hastalarda Serum bcl-2 Düzeyleri**

DURANYILDIZ D., OĞUZ SOYDİNC H., CAMLICA H., TAŞ F., YASASEVER V., TOPUZ E.  
TÜRK ONKOLOJİ DERGİSİ, vol.19, no.4, pp.131-133, 2004 (ESCI)

**XXXVII. Metastatik Malign Melanomlu Hastalarda TNF-a ve Eritropoeitin Prognostik Faktör Olarak Değerli mi?**

OĞUZ SOYDİNC H., DURANYILDIZ D., CAMLICA H., TAŞ F., YASASEVER V.  
TÜRK ONKOLOJİ DERGİSİ, vol.19, no.2, pp.43-45, 2004 (ESCI)

- XXXVIII. **Clinical usefulness of serum assays of carcinoembryonic antigen and beta 2-microglobulin in the diagnosis and discrimination of metastasis of lung cancer**  
Taş F., Aydiner A., Yasasever V., Dişçi R., Topuz E.  
Turkish Journal of Cancer, vol.30, pp.148-154, 2000 (Scopus)

## Books & Book Chapters

- I. **The role of surgical methods in the treatment of anorectal malignant melanoma (AMM).**  
VATANSEVER S., TAŞ F., Yıldız I., Kilic L., Ciftci R., Karabulut S., KESKİN S.  
Acta Chirurgica Belgica, İstanbul, 2013

## Refereed Congress / Symposium Publications in Proceedings

- I. **Prognostic Importance of BRAF and PTEN Proteins in Patients with Malignant Melanoma**  
Bilgin Doğru E., Tilgen Yasasever C., Serilmez M., Taş F., Duranyıldız H. D., Oğuz Soydiñç H.  
IX. INTERNATIONAL CONGRESS OF MOLECULAR MEDICINE "MOLECULAR MEDICINE IN LIFE SCIENCES", İstanbul, Turkey, 18 - 20 December 2023, pp.1
- II. **Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma**  
Gurbuz M., DOĞAN İ., Utkan G., TAŞ F.  
ESMO Asia Virtual Congress, ELECTR NETWORK, 20 - 22 November 2020, vol.31
- III. **A case with Factor X Deficiency and Malignant Melanoma**  
KOÇ ŞENOL S. B., BAY S., ZÜLFİKAR O. B., TAŞ F., KEBUDİ R.  
ISTH 2017 CONGRESS, 8 - 13 July 2017
- IV. **Circulating interleukin-18 (IL-18) as a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma.**  
Afsar C. U., Karabulut M., KARABULUT S., Tuna S., Alis H., Gonenc M., Dagoglu N., Bilgin E., TAŞ F.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- V. **Diagnostic and prognostic roles of serum interleukin-32 (IL-32) levels in patients with pancreatic adenocarcinoma.**  
KARABULUT S., Afsar C. U., Yasasever V., Karabulut M., Erturk K., Alis H., Gunaldi M., Peker K. D., Dagoglu N., TAŞ F.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- VI. **Serum Hepatosit Büyüme Faktörünün Akciğer Kanseri Hastalarında Tanısal Değeri**  
ŞEN F., BOZBEY H., ÇİFTÇİ R., KILIÇ L., YILDIZ İ., TAŞTEKİN D., ÇELEBİ K., ERTÜRK K., GÜRDAL N., OĞUZ SOYDİÑÇ H., et al.  
21. Ulusal Kanseri Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.1
- VII. **Clinical significance of serum transforming growth factor beta 1 (TGFB1) level in breast cancer.**  
CİFTCİ R., Tas F., Kilic L., Vatansever S., KARABULUT S.  
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- VIII. **Clinical significance of serum macrophage migration inhibitory factor (MIF) level in breast cancer.**  
CİFTCİ R., Tas F., AKSİT E., Vatansever S., KARABULUT S., Sen F., YILDIZ İ., Keskin S., BOZBEY H. U., Kilic L., et al.  
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- IX. **Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in lung cancer.**  
KARABULUT S., Tastekin D., CİFTCİ R., Tambas M., DAGOGLU N., Guveil M. E., Tas F., Duranyıldız D., Aydiner A.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32

- X. **Clinical significance of serum caveolin-1 levels in melanoma.**  
Tastekin D., KARABULUT S., DURANYILDIZ D., Tas F.  
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XI. **Epitelyal Over Kanserli Hastalarda Yüksek Serum Epidermal Büyüme Faktör Reseptörü (EGFR) Düzeyleri Kötü Progresyonsuz Sağkalımla İlişkilidir**  
Karabulut S., Ciftci R., Tastekin D., TİLGEN YASASEVER C., VATANSEVER S., Duranyildiz D., TAŞ F., Aydiner A., SAİP P. M.  
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.428
- XII. **Epitelyal Over Kanserinin Belirlenmesi Üzerinde Protease Activated Receptor-1 (PAR-1) Düzeylerinin Herhangi Bir Tanısal Değeri Var Mıdır?**  
Karabulut S., Ciftci R., Vatansever S., TAŞ F., TİLGEN YASASEVER C., YASASEVER F. V., Aydiner A., SAİP P. M.  
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.421
- XIII. **Küçük hücreli dışı akciğer kanserli hastalarda anjiyogenik markırların prognostik ve prediktif rolü**  
KESKİN S., KILIC L., YILDIZ I., ÇİFTÇİ R., KARABULUT S., ŞEN F., EKENEL M., AYDOĞAN F., TAŞ F.  
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 March 2014 - 23 April 2013, pp.333
- XIV. **Serum Transforme Edici Büyüme Faktörü-Beta1 (TGF-B1) Seviyelerinin Epitelyal Over Kanserli Hastalarda Klinik Önemi**  
Karabulut S., Ciftci R., Tastekin D., VATANSEVER S., TAŞ F., TİLGEN YASASEVER C., DURANYILDIZ H. D., Aydiner A., SAİP P. M.  
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.421
- XV. **Akciğer Karsinomlu Hatalarda VCAM-1 ve EPCAM Serum Konsantrasyonlarının Klinik Önemi**  
Tastekin D., Karabulut S., TAŞ F., Ciftci R., TİLGEN YASASEVER C., DURANYILDIZ H. D.  
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.572
- XVI. **Serum Makrofaj Migrasyon İnhibitör Faktörü (MIF) Düzeylerinin Epitelyal Over Kanserli Hastalarda Tanısal, Prediktif ve Prognostik Rolü**  
Karabulut S., Ciftci R., Tastekin D., Vatansever S., Keskin S., Yildiz I., TİLGEN YASASEVER C., Duranyildiz D., Aydiner A., SAİP P. M., et al.  
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.420
- XVII. **Meme Kanserli Hastalarda Serum Par-1 (Protease Activated Receptor-1) Düzeylerinin Klinik Açıdan Önemi**  
Ciftci R., Karabulut S., Aksit E., TAŞ F., TİLGEN YASASEVER C., VATANSEVER S., DURANYILDIZ H. D., Kilic L.  
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.500
- XVIII. **Clinical significance of serum LDH, CEA and CA19-9 levels in metastatic pancreatic cancer**  
Karabulut S., Ciftci R., Sen F., Tas F.  
European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Netherlands, 27 September - 01 October 2013, vol.49
- XIX. **Clinical significance of coagulation assays in metastatic pancreas adenocarcinoma**  
Karabulut S., Kilic L., Ciftci R., Yildiz I., Vatansever S., Keskin S., Tas F.  
European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Netherlands, 27 September - 01 October 2013, vol.49
- XX. **Prognostic factors in metastatic pancreatic cancer: Older patients have poorer prognosis**  
Ciftci R., Karabulut S., Aydoğan F., Kilic L., Keskin S., Yildiz I., Vatansever S., Tas F.  
European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Netherlands, 27 September - 01 October 2013, vol.49
- XXI. **Comparison of mucosal and cutaneous melanoma in the head and neck region: Different clinical features and similar outcomes.**  
Ciftci R., Keskin S., Karabulut S., Yildiz I., Kilic L., Sen F., Tastekin D., Tas F.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31

May - 04 June 2013, vol.31

- XXII. **Coagulation assays in breast cancer: Correlation of plasma D-dimer with tumor load and invasiveness in breast cancer patients.**  
Karabulut S., Kilic L., Ciftci R., Yildiz I., Sen F., Keskin S., Tastekin D., Tas F.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XXIII. **Türk Toplumundaki Meme Kanseri Hastalarında BRCA Mutasyon Dağılımlarının Klinik Faktörlerle İlişkisi**  
Kılıç I., ŞEN F., Yıldız I., Keskin S., KARANLIK H., EKENEL M., TUNÇER Ş. B., YAZICI H., TAŞ F.  
20.Ulusal Kanseri Kongresi, Antalya, Turkey, 20 - 23 April 2013
- XXIV. **Meme kanseri hastalarında plazma D-Dimer düzeylerinin tümör yükü ve metastazı ile ilişkisi**  
KILIC L., ŞEN F., YILDIZ İ., KESKİN S., EKENEL M., SERİLMEZ M., DURANYILDIZ D., TAŞ F.  
4. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2012, pp.250
- XXV. **Akciğer kanserinde koagülasyon testlerinin prognostik önemi**  
KILIC L., YILDIZ İ., ŞEN F., EKENEL M., KESKİN S., BİLGİN DOĞRU E., DURANYILDIZ D., TAŞ F.  
4. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2012, pp.150-151
- XXVI. **İleri Evre Klasik Kaposi Sarkomlu Hastaların Birinci Seçim Tedavisinde Oral Etoposid**  
ŞEN F., Yıldız I., Kılıç I., Keskin S., KARANLIK H., TUNÇER Ş. B., TAŞ F.  
4. Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 22 March 2012, pp.284
- XXVII. **Noncutaneous melanoma have distinct features from each other and cutaneous melanoma**  
KESKİN S., EKENEL M., YILDIZ İ., KILIÇ L., KARABULUT S., ŞEN F., AYDOĞAN F., TAŞ F.  
2nd Mediterranean Multidisciplinary Oncology Forum, İstanbul, Turkey, 17 - 19 November 2011
- XXVIII. **Koroidal melanomda evreleme ve yeniden evrelemede PET/BT'nin rolü**  
KUYUMCU S., ŞANLI Y., HAS ŞİMŞEK D., TÜRKMEN C., KESKİN S., TAŞ F., MUDUN A.  
23. ULUSAL NÜKLEER TIP KONGRESİ, İzmir, Turkey, 27 April - 01 May 2011
- XXIX. **Kolon ve rektum karsinomlu hastalarda EGFR IL-6 ve IL-10 düzeyleri**  
SERİLMEZ M., OĞUZ SOYDİNÇ H., KILIÇ L., UZUNOĞLU S., TAŞ F., DURANYILDIZ D.  
19.Ulusal Kanseri Kongresi, Antalya, Turkey, 20 - 24 April 2011, pp.1
- XXX. **The use of PET/CT for staging and restaging purpose in malignant melanoma: Preliminary results**  
ŞANLI Y., HAS ŞİMŞEK D., GEÇER M. F., YILMAZ E., EKMEKÇİ Ş., TÜRKMEN C., ADALET I., ÜNAL S. N., KAYTAN SAĞLAM E., TAŞ F., et al.  
23. Annual Congress of European Association of Nuclear Medicine, Viyana, Austria, 9 - 13 October 2010, vol.37, pp.443
- XXXI. **Akciğer kanseri hastalarında kemoterapi ve radyoterapinin hematolojik parametreler üzerine etkisi**  
SERİLMEZ M., OĞUZ SOYDİNÇ H., TAŞ F., DURANYILDIZ D.  
21. Ulusal Biyokimya Kongresi, İstanbul, Turkey, 28 - 31 October 2009, pp.1
- XXXII. **Platin-bazlı kemoterapi alan hastalarda üre- kreatinin değerleri**  
OĞUZ SOYDİNÇ H., SERİLMEZ M., TAŞ F., YASASEVER V.  
21. Ulusal Biyokimya Kongresi, İstanbul, Turkey, 28 - 31 October 2009, pp.1
- XXXIII. **İleri Evre Küçük Hücreli Dışı Akciğer Kanseri Adezyon Molekülü ICAM-1 ve E-Selectin'in Serum Düzeyleri**  
GUNEY N., OĞUZ SOYDİNÇ H., DERİN D., TAŞ F., CAMLICA H., DURANYILDIZ D., YASASEVER V., TOPUZ E.  
XVIII. Ulusal Kanseri Kongresi, Antalya, Turkey, 21 - 26 April 2009, pp.1
- XXXIV. **Akciğer Kanseri IL-6 ve IL-1beta**  
YASASEVER V., DURANYILDIZ D., OĞUZ SOYDİNÇ H., CAMLICA H., TAŞ F.  
XVIII. Ulusal Kanseri Kongresi, Antalya, Turkey, 21 - 26 April 2009, pp.1
- XXXV. **Akciğer Kanseri IL-12'nin Yeri**  
DURANYILDIZ D., OĞUZ SOYDİNÇ H., CAMLICA H., TAŞ F., YASASEVER V.  
XVIII. Ulusal Kanseri Kongresi, Antalya, Turkey, 21 - 26 April 2009, pp.1
- XXXVI. **Bone Markers in Bone Metastases**  
OĞUZ SOYDİNÇ H., DURANYILDIZ D., CAMLICA H., TAŞ F., YASASEVER V.

XXIII. IATMO Conference: Cancer, Cell Death and Differentiation, Trieste, Italy, 19 - 21 October 2007, pp.1

XXXVII. **Survivin Levels in Cancer**

OĞUZ SOYDİNC H., DURANYILDIZ D., CAMLICA H., TAŞ F., YASASEVER V.

XXIII. IATMO Conference: Cancer, Cell Death and Differentiation, Trieste, Italy, 19 - 21 October 2007, pp.1

XXXVIII. **The role of surgery and radiotherapy in treatment of soft tissue sarcomas of the head and neck region: Review of 30 cases**

Taş F., Fayda M., Aksu G., Ağaoğlu F. Y., Karadeniz A. N., Darendeliler E., Altun M., Uygun K.

American Society of Clinical Oncology (ASCO) 2007 Annual Meeting, Illinois, United States Of America, 1 - 05 June 2007, vol.25, pp.726

XXXIX. **Kemik Metastazlarında Osteokalsin**

OĞUZ SOYDİNC H., CAMLICA H., DURANYILDIZ D., TAŞ F., YASASEVER V.

XVII. Ulusal Kanseri Kongresi, Antalya, Turkey, 19 - 23 April 2007, pp.1

XL. **Akciğer Kanseriinde Anjiogenik Faktörler'**

TAŞ F., OĞUZ SOYDİNC H., UYGUN K., CİCİN İ., SELAM M., CAMLICA H., DURANYILDIZ D., YASASEVER V.

XVII. Ulusal Kanseri Kongresi, Antalya, Turkey, 19 - 23 April 2007, pp.1

XLI. **IL-13 ve Akciğer Kanseri**

OĞUZ SOYDİNC H., TAŞ F., UYGUN K., CİCİN İ., SELAM M., CAMLICA H., DURANYILDIZ D., YASASEVER V.

XVII. Ulusal Kanseri Kongresi, Antalya, Turkey, 19 - 23 April 2007, pp.1

XLII. **Kemik Metastazlarında Osteoprotegerin**

DURANYILDIZ D., OĞUZ SOYDİNC H., CAMLICA H., TAŞ F., YASASEVER V.

XVII. Ulusal Kanseri Kongresi, Antalya, Turkey, 19 - 23 April 2007, pp.1

XLIII. **Malign Melanomda MIF'in Önemi'**

DURANYILDIZ D., OĞUZ SOYDİNC H., CAMLICA H., TAŞ F., YASASEVER V.

XVII. Ulusal Kanseri Kongresi, Antalya, Turkey, 19 - 23 April 2007, pp.1

XLIV. **Evre IV Küçük Hücreli dışı Akciğer Kanseriinde Serum Vasküler Endotelial Büyüme Faktörü ve Bcl-2 Düzeyleri Arasındaki İlişki'**

ERTAN E., TAŞ F., OĞUZ SOYDİNC H., YAZAR A., YASASEVER V., ÖZGÜL A., YILMAZ V.

XVII. Ulusal Kanseri Kongresi, Antalya, Turkey, 19 - 23 April 2007, pp.1

XLV. **The Role of IL-13 in Lung Cancer**

OĞUZ SOYDİNC H., DURANYILDIZ D., CAMLICA H., TAŞ F., YASASEVER V.

II. Ulusal Moleküler Tıp Kongresi, İstanbul, Turkey, 24 March - 26 April 2007, pp.1

XLVI. **The Role of UPAR in Lung Cancer**

DURANYILDIZ D., OĞUZ SOYDİNC H., CAMLICA H., TAŞ F., YASASEVER V.

II. Ulusal Moleküler Tıp Kongresi, İstanbul, Turkey, 24 March - 26 April 2007, pp.1

XLVII. **The Role of uPAR in Breast Cancer: A Proteolytic System Component**

OĞUZ SOYDİNC H., CAMLICA H., DURANYILDIZ D., GÜNEY N., DERİN D., TAŞ F., DALAY N., YASASEVER V.

31st FEBS Congress "Molecules in Health and Disease, İstanbul, Turkey, 24 - 29 June 2006, pp.1

XLVIII. **İleri Evre Over Kanseriinde Leptinin Önemi**

OĞUZ SOYDİNC H., CAMLICA H., DURANYILDIZ D., TAŞ F., TOPUZ E., YASASEVER V.

I.Tıbbi Onkoloji Kongresi, Antalya, Turkey, 29 March - 02 April 2006, pp.1

XLIX. **İleri Evre Küçük Hücreli Dışı Akciğer Kanseriinde Matriks Metalloproteinaz-9, Vasküler Endotelial Büyüme Faktör ve bcl-2 Düzeylerinin Prognoz ve Tedavi ile İlişkileri**

YAZAR A., TAŞ F., OĞUZ SOYDİNC H., ERTAN E., YASASEVER V., CAMLICA H., ERALP Y., TOPUZ E.

I.Tıbbi Onkoloji Kongresi, Antalya, Turkey, 29 March - 02 April 2006, pp.1

L. **Epitelial Over Kanseri Hastalarda Serum Leptin Düzeyinin Ca125 ve Sağkalım ile İlişkisi**

YAZAR A., TAŞ F., OĞUZ SOYDİNC H., CAMLICA H., ERALP Y., SAİP P., AYDINER A., TOPUZ E.

I.Tıbbi Onkoloji Kongresi, Antalya, Turkey, 29 March - 02 April 2006, pp.1

LI. **Malign Melanomda VEGF, MMP-3 ve Bcl-2 Düzeyleri**

OĞUZ SOYDİNC H., DURANYILDIZ D., CAMLICA H., TAŞ F., TOPUZ E., YASASEVER V.

I.Tıbbi Onkoloji Kongresi, Antalya, Turkey, 29 March - 02 April 2006, pp.1

LII. **Meme Kanseriinde IL-8 ve IL-12 Düzeyleri**

DERİN D., OĞUZ SOYDİNCİ H., GÜNEY N., TAŞ F., CAMLICA H., YASASEVER V., DURANYILDIZ D., TOPUZ E.  
I.Tıbbi Onkoloji Kongresi, Antalya, Turkey, 29 March - 02 April 2006, pp.1

**LIII. Malign Melanomda Anjiogenik Faktörler**

OĞUZ SOYDİNCİ H., CAMLICA H., DURANYILDIZ D., TAŞ F., TOPUZ E., YASASEVER V.  
I.Tıbbi Onkoloji Kongresi, Antalya, Turkey, 29 March - 02 April 2006, pp.1

**LIV. Meme Kanserinde Serum ve İdrar Survivin Değerleri**

GÜNEY N., OĞUZ SOYDİNCİ H., DERİN D., TAŞ F., CAMLICA H., DURANYILDIZ D., YASASEVER V., TOPUZ E.  
I.Tıbbi Onkoloji Kongresi, Antalya, Turkey, 29 March - 02 April 2006, pp.1

**LV. Malign Melanomda Anjiogenik Faktörler ile Prognostik Faktörlerin İlişkisi**

OĞUZ SOYDİNCİ H., DURANYILDIZ D., CAMLICA H., TAŞ F., TOPUZ E., YASASEVER V.  
I.Tıbbi Onkoloji Kongresi, Antalya, Turkey, 29 March - 02 April 2006, pp.1

**LVI. İleri Evre Küçük Hücreli Dışı Akciğer Kanserinde Matriks Metalloproteinaz-9 Düzeyinin Tedavi ile Değişiminin Tedaviye Cevap Ve Sağkalım İle İlişkisi**

YAZAR A., TAŞ F., OĞUZ SOYDİNCİ H., ERTAN E., YASASEVER V., CAMLICA H., SAİP P., AYDINER A.  
I.Tıbbi Onkoloji Kongresi, Antalya, Turkey, 29 March - 02 April 2006, pp.1

**LVII. Serum and urine survivin levels in breast cancer**

Güney N., SOYDİNE H., Derin D., Tas F., Çamlıca H., Duranyıldız D., Yasasever V., Topuz E.  
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.89

**LVIII. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer**

Karagol H., Saip P., Uygun K., Caloglu M., Eralp Y., Tas F., Aydinler A., Topuz E.  
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.174

**LIX. Serum levels of leptin and proinflammatory cytokines in advanced stage non-small cell lung cancer.**

Topuz E., Tas F., Argon A., Yildiz D., Oguz H., Yasasever V., Eralp Y., Aydinler A.  
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23

**LX. Brain metastases occurrence among metastatic breast cancer: A single oncology center experience.**

Uygun K., Karagol H., Tokatli F., Caloglu M., Donmez S., Tas F.  
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23

**LXI. Serum Levels of Leptin and Proinflammatory Cytokines in Advanced Stage Non-small Cell Lung Cancer**

TOPUZ E., TAŞ F., ARGON A., DURANYILDIZ D., OĞUZ SOYDİNCİ H., YASASEVER V., ERALP Y., AYDINER A.  
2005 ASCO Annual Meeting, Orlando/Florida, United States Of America, 12 - 17 May 2005, pp.1

**LXII. Malign Melanomda Matriks Metalloproteinazlar**

OĞUZ SOYDİNCİ H., DURANYILDIZ D., TAŞ F., CAMLICA H., TOPUZ E., YASASEVER V.  
XVI. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2005, pp.1

**LXIII. Malign Melanom ve bcl-2**

OĞUZ SOYDİNCİ H., DURANYILDIZ D., TAŞ F., CAMLICA H., TOPUZ E., YASASEVER V.  
XVI. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2005, pp.1

**LXIV. Malign Melanomda Apoptozis**

DURANYILDIZ D., OĞUZ SOYDİNCİ H., TAŞ F., CAMLICA H., TOPUZ E., YASASEVER V.  
XVI. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2005, pp.1

**LXV. Malign Melanomda IL-6, TNF- $\alpha$  ve EPO'nun Önemi**

DURANYILDIZ D., OĞUZ SOYDİNCİ H., TAŞ F., CAMLICA H., TOPUZ E., YASASEVER V.  
XVI. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2005, pp.1

**LXVI. Malign Melanomlu Hastaların Serum-İdrar Survivin Düzeyleri**

OĞUZ SOYDİNCİ H., DURANYILDIZ D., TAŞ F., CAMLICA H., TOPUZ E., YASASEVER V.  
XVI. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2005, pp.1

**LXVII. Kemik Metastazlarında Anjiogenik Faktörler**

- DURANYILDIZ D., OĞUZ SOYDİNÇ H., DERİN D., TAŞ F., CAMLICA H., TOPUZ E., YASASEVER V.  
XVI. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2005, pp.1
- LXVIII. **Akciğer Kanserinde VEGF'in Rolü**  
OĞUZ SOYDİNÇ H., DURANYILDIZ D., CAMLICA H., USTUNER Z., TAŞ F., TOPUZ E., YASASEVER V.  
Ulusal Moleküler Tıp Kongresi, İstanbul, Turkey, 16 - 19 April 2005, pp.1
- LXIX. **Matriksmetalloproteinazlar (MMP) ve Malign Melanom**  
OĞUZ SOYDİNÇ H., DURANYILDIZ D., CAMLICA H., TAŞ F., YASASEVER V.  
18. Ulusal Biokimya Kongresi, Trabzon, Turkey, 15 - 19 May 2004, pp.1
- LXX. **Malign Melanom ve Apoptotik Proteinler**  
OĞUZ SOYDİNÇ H., DURANYILDIZ D., CAMLICA H., TAŞ F., YASASEVER V.  
18. Ulusal Biokimya Kongresi, Trabzon, Turkey, 15 - 19 May 2004, pp.1
- LXXI. **Chemotherapy Induced Changes in Neopterin and 90K Protein Levels**  
YASASEVER V., Çamlıca H., TAŞ F., DEMOKAN S., DURANYILDIZ D., KURUL S., DALAY N.  
17th International Conference of Human Tumor Marker, China, 1 - 04 March 2000, vol.15, no.1, pp.39
- LXXII. **Oral etoposide in patients with small cell lung cancer**  
TOPUZ E., TAŞ F., AYDINER A., DEMİR C., SAİP P. M., SALEPÇİ T., KARADENİZ A. N., ERTÜRK N.  
EUROPEAN JOURNAL OF CANCER, Oxford, United Kingdom, 01 September 1997, vol.33, no.8, pp.1072
- LXXIII. **Oral etoposide in patients (pts) with Kaposi's sarcoma (KS)**  
AYDINER A., TAS F., SAİP P. M., KARADENİZ A. N., DEMİR C., SALEPÇİ T., TOPUZ E.  
EUROPEAN JOURNAL OF CANCER, Oxford, United Kingdom, 01 September 1997, vol.33, no.8, pp.1178

## Supported Projects

DURANYILDIZ H. D., SERİLMEZ M., OĞUZ SOYDİNÇ H., TAŞ F., GEZER U., KİZİR A., Project Supported by Higher Education Institutions, Akciğer Kanserinde LYVE-1'in Önemi, 2015 - 2017

## Metrics

Publication: 347

Citation (WoS): 3206

Citation (Scopus): 3511

H-Index (WoS): 29

H-Index (Scopus): 30

## Non Academic Experience

İstanbul Üniversitesi Onkoloji Enstitüsü

İstanbul Üniversitesi Onkoloji Enstitüsü

İstanbul Haseki Hastanesi

Isparta Askeri Hastanesi